

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, open-label, single-arm, phase II study (CRC-PIPAC).

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030408
Article Type:	Protocol
Date Submitted by the Author:	12-Mar-2019
Complete List of Authors:	Rovers, Koen; Catharina Hospital, Surgery Lurvink, Robin; Catharina Hospital, Surgery Wassenaar, Emma; Sint Antonius Hospital, Surgery Kootstra, Thomas; Sint Antonius Hospital, Surgery Scholten, Harm; Catharina Hospital, Anaesthesiology Tajzai, Rudaba; Catharina Hospital, Clinical Pharmacy Deenen, Maarten; Catharina Hospital, Clinical Pharmacy Nederend, Joost; Catharina Hospital, Radiology Lahaye, Max; Netherlands Cancer Institute, Radiology Huysentruyt, Clément; Catharina Hospital, Pathology van 't Erve, Iris; Netherlands Cancer Institute, Pathology Fijneman, Remond; Netherlands Cancer Institute, Pathology Constantinides, Alexander; UMC Utrecht, Imaging and Cancer Kranenburg, Onno; UMC Utrecht, Imaging and Cancer Los, Maartje; Sint Antonius Hospital, Medical Oncology Thijs, Annemarie; Catharina Hospital, Medical Oncology Creemers, Geert-Jan; Catharina Hospital, Medical Oncology Burger, Jacobus; Catharina Hospital, Surgery Wiezer, René; Sint Antonius Hospital, Surgery Boerma, Djamila ; Sint Antonius Hospital, Surgery Nienhuijs, Simon W.; Catharina Hospital, Surgery de Hingh, Ignace; Catharina Hospital, Surgery
Keywords:	PIPAC, Peritoneal metastases, Colorectal cancer, Colorectal surgery < SURGERY, Gastrointestinal tumours < ONCOLOGY, Intraperitoneal chemotherapy

SCHOLARONE™
Manuscripts

Title

Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a multicentre, open-label, single-arm, phase II study (CRC-PIPAC).

Corresponding author

Prof. dr. I.H.J.T. (Ignace) de Hingh, MD, PhD;
Department of Surgery, Catharina Hospital;
PO Box 1350, 5602 ZA, Eindhoven, Netherlands;
E-mail: ignace.d.hingh@catharinaziekenhuis.nl;
Telephone: +31402397150.

Authors

Koen P. Rovers¹; Robin J. Lurvink⁴; Emma C.E. Wassenaar²; Thomas J.M. Kootstra²; Harm J. Scholten³; Rudaba Tajzai^{1,4}; Maarten J. Deenen^{4,5}; Joost Nederend⁶; Max J. Lahaye⁷; Clément J.R. Huysentruyt⁸; Iris van 't Erve⁹; Remond J.A. Fijneman⁹; Alexander Constantinides¹⁰; Onno Kranenburg¹⁰; Maartje Los¹¹; Anna M.J. Thijs¹²; Geert-Jan M. Creemers¹²; Jacobus W.A. Burger¹; Marinus J. Wiezer²; Djamila Boerma²; Simon W. Nienhuijs¹; Ignace H.J.T. de Hingh^{1,13}.

Affiliations

¹Department of Surgery, Catharina Hospital, Eindhoven, Netherlands;

²Department of Surgery, St. Antonius Hospital, Nieuwegein, Netherlands;

³Department of Anaesthesiology, Catharina Hospital, Eindhoven, Netherlands;

⁴Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, Netherlands;

⁵Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, Netherlands;

⁶Department of Radiology, Catharina Hospital, Eindhoven, Netherlands;

⁷Department of Radiology, Netherlands Cancer Institute, Amsterdam, Netherlands;

⁸Department of Pathology, Catharina Hospital, Eindhoven, Netherlands;

⁹Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands;

¹⁰Imaging and Cancer, Utrecht Platform for Organoid Technology, University Medical Centre Utrecht, Utrecht, Netherlands;

¹¹Department of Medical Oncology, St. Antonius Hospital, Nieuwegein, Netherlands;

¹²Department of Medical Oncology, Catharina Hospital, Eindhoven, Netherlands;

1
2
3 1 ¹³Grow – School for Oncology and Developmental Biology, Maastricht University, Maastricht,
4
5 2 Netherlands

6
7 3
8 4 **Word count**

9
10 5 3988.

11
12 6
13 7 **Abstract**

14 8 *Introduction:* Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy with
15 9 oxaliplatin (ePIPAC-OX) is offered as a palliative treatment option for patients with isolated
16 10 unresectable colorectal peritoneal metastases (PM) in several centres worldwide. However, little is
17 11 known about its feasibility, safety, tolerability, efficacy, costs, and pharmacokinetics in this setting. This
18 12 study aims to explore these parameters in patients with isolated unresectable colorectal PM who
19 13 receive repetitive ePIPAC-OX as a palliative monotherapy.

20 14 *Methods and analysis:* This multicentre, open-label, single-arm, phase II study is performed in two
21 15 Dutch tertiary referral hospitals for the surgical treatment of colorectal PM. Eligible patients are adults
22 16 who have histologically or cytologically proven isolated unresectable PM of a colorectal or appendiceal
23 17 carcinoma, a good performance status, adequate organ functions, and no symptoms of
24 18 gastrointestinal obstruction. Instead of standard palliative treatment, enrolled patients receive
25 19 laparoscopy-controlled ePIPAC-OX (92 mg/m² body-surface area [BSA]) with intravenous leucovorin
26 20 (20 mg/m² BSA) and bolus 5-fluorouracil (400 mg/m² BSA) every six weeks. Four weeks after each
27 21 procedure, patients undergo clinical, radiological, and biochemical evaluation. ePIPAC-OX is repeated
28 22 until disease progression, after which standard palliative treatment is (re)considered. The primary
29 23 outcome is the number of patients with major toxicity (grade ≥ 3 according to the Common
30 24 Terminology Criteria for Adverse Events v4.0) up to four weeks after the last ePIPAC-OX. Secondary
31 25 outcomes are the environmental safety of ePIPAC-OX, procedure-related characteristics, minor
32 26 toxicity, organ-specific toxicity, postoperative complications, hospital stay, readmissions, quality of life,
33 27 costs, pharmacokinetics of oxaliplatin, progression-free survival, overall survival, and the radiological,
34 28 histopathological, cytological, biochemical, and macroscopic tumour response.

35 29 *Ethics and dissemination:* This study is approved by an ethics committee, the Dutch competent
36 30 authority, and the institutional review boards of both study centres. Results are intended for
37 31 publication in peer-reviewed medical journals and for presentation to patients, healthcare
38 32 professionals, and other stakeholders.

39 33 *Registration:* ClinicalTrials.gov/NCT03246321, ISRCTN/ISRCTN89947480, NTR/NTR6603,
40 34 EudraCT/2017-000927-29.

1 2 3 **Keywords**

4
5 2 Colorectal surgery (from list); gastrointestinal tumours (from list); colorectal cancer (not from list);
6
7 3 peritoneal metastases (not from list); PIPAC (not from list); intraperitoneal chemotherapy (not from
8
9 4 list).

10 11 **Strengths and limitations of this study**

- 12
13 7 • This is the first study that prospectively explores predefined endpoints regarding the
14
15 8 feasibility, safety, and efficacy of repetitive ePIPAC-OX as a palliative monotherapy in patients
16
17 9 with isolated unresectable colorectal PM.
- 18
19 10 • Unlike other studies, repetitive ePIPAC-OX is administered as a palliative monotherapy,
20
21 11 thereby minimising the influence of concurrent palliative systemic therapy on study outcomes.
- 22
23 12 • Apart from exploring clinical outcomes such as feasibility, safety, and efficacy, this study
24
25 13 includes assessment of quality of life and costs as well as pharmacokinetic and translational
26
27 14 side studies.
- 28
29 15 • The broad eligibility criteria could lead to enrolment of prognostically heterogeneous patients
30
31 16 in different lines of palliative treatment, which could impede the interpretation of efficacy
32
33 17 outcomes.

34 35 **INTRODUCTION**

36
37 20 After the liver, the peritoneum is the second most common isolated metastatic site of colorectal
38
39 21 cancer.[1,2] The majority of patients with isolated colorectal peritoneal metastases (PM) does not
40
41 22 qualify for curative intent surgical treatment,[3] mostly due to insufficient condition or unresectable
42
43 23 disease. Palliative systemic therapy is the standard treatment for patients with isolated unresectable
44
45 24 colorectal PM.[4] Although its increasing use has improved the outcomes of these patients,[3]
46
47 25 palliative systemic therapy appears less effective for isolated colorectal PM than for isolated non-
48
49 26 peritoneal colorectal metastases.[5] This phenomenon may be explained by a relatively low
50
51 27 intraperitoneal concentration of systemically administered chemotherapy.[6] Moreover, a relatively
52
53 28 high systemic concentration could cause systemic toxicity. Intraperitoneal administration of
54
55 29 chemotherapy is thought to increase locoregional efficacy and decrease systemic toxicity through a
56
57 30 favourable peritoneum-plasma concentration ratio.[6-8] However, intraperitoneal chemotherapy
58
59 31 seems to have three major limitations: a poor direct tissue penetration, an inhomogeneous
60
32 intraperitoneal drug distribution, and dose-limiting local toxicity.[9,10] This has encouraged
33 development of new intraperitoneal drug delivery systems that aim to overcome these limitations.

1
2
3 1 Currently, pressurised intraperitoneal aerosol chemotherapy (PIPAC) is one of these systems that
4 2 internationally gains the most attention.
5
6 3

4 **Pressurised intraperitoneal aerosol chemotherapy (PIPAC)**

5 PIPAC is a laparoscopy-controlled repetitive intraperitoneal administration of low-dose chemotherapy
6 as a pressurised aerosol.[11,12] It combines the theoretical pharmacokinetic advantages of low-dose
7 intraperitoneal chemotherapy (i.e. low toxicity, high intraperitoneal concentration, low systemic
8 concentration) with the principles of an aerosol (homogeneous intraperitoneal distribution) and intra-
9 abdominal pressure (deep tissue penetration).[13-20] Two groups systematically reviewed results of
10 non-comparative clinical studies that assessed the feasibility, safety, tolerability, and preliminary
11 efficacy of PIPAC with various drugs for PM of various origins.[21,22] They concluded that PIPAC is a
12 safe, feasible, and well tolerated treatment with good preliminary response rates.[21,22] These
13 preliminary conclusions have led to an increasing acceptance of PIPAC as a palliative treatment option
14 for PM in several centres worldwide.[23] In these centres, patients with isolated unresectable
15 colorectal PM usually receive PIPAC with oxaliplatin (PIPAC-OX) in an empirically chosen dosage of 92
16 mg/m² body-surface area (BSA) every four to six weeks.[23] Some centres use electrostatic
17 precipitation of the aerosol during PIPAC-OX (ePIPAC-OX),[24,25] since this could increase tissue
18 penetration of oxaliplatin.[26]

20 **PIPAC for colorectal PM**

21 Several clinical studies included patients who received repetitive PIPAC-OX for colorectal PM.[27-36]
22 However, the vast majority of these studies reported outcomes of entire cohorts that received
23 repetitive PIPAC with various drugs for PM of various origins without presenting subgroup analyses of
24 patients who received PIPAC-OX for colorectal PM.[27-34] Only two studies reported separate
25 outcomes of repetitive PIPAC-OX for colorectal PM.[35,36] By using a prospectively maintained
26 database, Teixeira-Farinha *et al* retrospectively included 20 patients with isolated colorectal PM who
27 received 37 procedures.[35] They concluded that repetitive PIPAC-OX causes a modest and transitory
28 inflammatory response without haematological, renal, or hepatic toxicity.[35] Demtröder *et al.*
29 retrospectively included 17 patients with isolated colorectal PM who received 48 procedures within
30 an off-label program.[36] They concluded that repetitive PIPAC-OX induces regression of pretreated
31 colorectal PM and that the toxicity seems to be low.[36] Both studies have a retrospective design
32 without predefined eligibility criteria and endpoints. Moreover, both studies included patients who
33 receive repetitive PIPAC-OX as a monotherapy as well as patients who receive PIPAC-OX in
34 combination with palliative systemic therapy. These shortcomings strongly impede the interpretation

1
2
3 1 of these studies. Besides, recently published case reports suggested that PIPAC-OX could lead to severe
4 2 hypersensitivity reactions and peritoneal sclerosis.[37,38]

3 4 **Rationale for this study**

5 In conclusion, little is known about the safety, tolerability, and efficacy of repetitive PIPAC-OX in
6 6 patients with isolated unresectable colorectal PM, whereas nothing is known about its costs and
7 7 pharmacokinetics. Specifically for repetitive ePIPAC-OX, all these outcomes have never been reported.
8 8 This questions the current use of repetitive (e)PIPAC-OX as a palliative treatment option for isolated
9 9 unresectable colorectal PM outside the framework of clinical study protocols. Ideally, these patients
10 10 are included in prospective studies with predefined eligibility criteria, interventions, and endpoints.
11 11 However, by the knowledge of the investigators, such studies are currently lacking and not
12 12 ongoing.[39] Therefore, this study aims to prospectively explore the safety, tolerability, preliminary
13 13 efficacy, costs, and pharmacokinetics of repetitive ePIPAC-OX as a palliative treatment for isolated
14 14 unresectable colorectal PM. Although implementation of PIPAC appears feasible and occupationally
15 15 safe,[21,22,24,40-43] there is no experience with PIPAC in the Netherlands. Hence, this study also aims
16 16 to assess the feasibility of implementation of ePIPAC-OX in two Dutch tertiary referral hospitals for the
17 17 surgical treatment of colorectal PM.

18 19 **Rationale for intervention**

20 Repetitive ePIPAC-OX may be administered as part of a bidirectional therapy with palliative systemic
21 21 therapy or as a monotherapy. When administered as a bidirectional therapy, the main objective is
22 22 maximising tumour response, probably at the cost of an increased treatment burden that could
23 23 interfere with quality of life. When administered as a monotherapy, the main objective is temporary
24 24 intraperitoneal disease stabilisation with minimal treatment burden and preservation of quality of life.
25 25 For this study, the investigators decided to administer repetitive ePIPAC-OX as a palliative
26 26 monotherapy with (re)consideration of standard palliative treatment upon progression. According to
27 27 internationally used protocols, ePIPAC-OX is administered in a dosage of 92 mg/m² at six-weekly
28 28 intervals.[23] The investigators actively followed two ongoing phase I studies in which repetitive PIPAC-
29 29 OX is administered in various pre-planned dosage levels to evaluate whether the dosage of oxaliplatin
30 30 in this study needs to be modified.[44,45] Before administration of ePIPAC-OX, patients receive
31 31 intravenous low-dose leucovorin with bolus 5-fluorouracil, since this is thought to potentiate the effect
32 32 of intraperitoneal oxaliplatin.[46,47]

33 34 **METHODS AND ANALYSIS**

35 **Design and setting**

1
2
3 1 This prospective, open-label, single-arm, phase II study is performed in two Dutch teaching hospitals
4 2 qualified as tertiary referral hospitals for the surgical treatment of colorectal PM.
5
6
7 3

8 4 **Eligibility criteria**

9 5 Eligible patients are adults who have:

- 10 6
- 11 7 ▪ a World Health Organisation (WHO) performance status of ≤ 1 ;
 - 12 8 ▪ histological or cytological proof of PM of a colorectal or appendiceal carcinoma;
 - 13 9 ▪ unresectable disease determined by abdominal computed tomography (CT) and a diagnostic
14 10 laparoscopy or laparotomy;
 - 15 11 ▪ adequate organ functions (haemoglobin ≥ 5.0 mmol/L, neutrophils $\geq 1.5 \times 10^9/L$, platelets ≥ 100
16 12 $\times 10^9/L$, serum creatinine $< 1.5 \times$ ULN, creatinine clearance ≥ 30 ml/min, and liver
17 13 transaminases $< 5 \times$ ULN);
 - 18 14 ▪ no symptoms of gastrointestinal obstruction;
 - 19 15 ▪ no radiological evidence of systemic metastases;
 - 20 16 ▪ no contraindications for oxaliplatin or 5-fluorouracil/leucovorin;
 - 21 17 ▪ no contraindications for a laparoscopy;
 - 22 18 ▪ no previous PIPAC-procedures.
- 23
24
25
26
27
28
29
30
31
32
33
34

35 20 Importantly, enrolment is allowed for patients with an unresected primary tumour (if asymptomatic)
36 21 and for patients in various lines of palliative treatment, including patients who refuse, have not had,
37 22 or do not qualify for first-line palliative systemic therapy. All potentially eligible patients are discussed
38 23 by a multidisciplinary team. Enrolled patients are informed about the potential consequences of
39 24 postponing or discontinuing standard palliative treatment by a medical oncologist prior to enrolment.
40
41
42
43
44

45 26 **Interventions and procedures**

46 27 *Figure 1* shows a flow chart of the study. *Table 1* presents a schedule of enrolment, interventions, and
47 28 assessments.
48
49

50 29
51 30
52 31
53 32
54 33
55 34
56 35
57
58
59
60

1 **Table 1.** Schedule of enrolment, interventions, and assessments.

	Study period				
	Enrolment/allocation	Post-enrolment			
		Outpatient clinics	Baseline radiology	Each ePIPAC-OX	1 week after each ePIPAC-OX
ENROLMENT/ALLOCATION					
Eligibility screen	X				
Informed consent	X				
INTERVENTIONS					
ePIPAC-OX			X		
Blood (organ functions, tumour markers)	X		X ^A		X
Pharmacokinetics (blood, urine, ascites, PM, normal peritoneum) ^B			X		
Translational research (blood, ascites, PM)			X ^C		
Thoracoabdominal computed tomography		X			X
Diffusion-weighted magnetic resonance imaging		X			X
Cytology (ascites or peritoneal washing)			X		
Histopathology (peritoneal biopsies)			X		
Questionnaires: quality of life		X		X	X
Questionnaires: costs ^D		X			X
ASSESSMENTS					
Baseline characteristics	X	X	X		
Toxicity			X	X	X
Environmental safety of ePIPAC-OX ^E			X		
Procedure-related characteristics			X		
Number of procedures in each patient, reasons for discontinuation			X	X	X
Organ-specific toxicity			X		X
Postoperative complications			X	X	X
Hospital stay			X		
Readmissions				X	X
Clinical evaluation			X	X	X
Radiological tumour response		X			X
Histopathological tumour response			X		
Cytological tumour response			X		
Macroscopic tumour response			X		
Biochemical tumour response			X		X
Quality of life		X		X	X
Costs		X			X
Progression-free survival			X	X	X
Overall survival			X	X	X

ePIPAC-OX electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin; PM peritoneal metastases; ^Adrawn on each postoperative day; ^Bblood is drawn before ePIPAC-OX and at 5, 10, 20, 30, 60, 120, 240, 360, and 1080 minutes after oxaliplatin injection during/after the first three procedures, urine is collected before ePIPAC-OX and on postoperative days 1, 3, 5, and 7, ascites/PM/normal peritoneum are collected directly after oxaliplatin injection; ^Cblood is drawn before ePIPAC-OX; ^DMCQ 4 weeks after each procedure, PCQ 4 weeks after each second procedure; ^Eonly during the first three procedures in the study.

2
3 ePIPAC-OX
4 The procedure-related principles of (e)PIPAC have been extensively described by Willaert *et al* and
5 Giger-Pabst *et al*.^[24,48] In this study, ePIPAC-OX is performed at six-weekly intervals by at least one
6 PIPAC-qualified surgeon in a standard operating room with laminar airflow. In both study centres, the
7 operating personnel attended procedures in experienced PIPAC centres before performing their first
8 procedure. All procedures are performed under general anaesthesia without antibiotic prophylaxis or
9 venous thromboembolism prophylaxis. Before each procedure, a checklist is used to ensure all

1 materials are available. The operating personnel wears appropriate chemotherapy-protective clothes
2 according to existing HIPEC protocols.

3 The Hasson technique is used to insert a 10 mm blunt tip balloon trocar through the abdominal
4 wall. After obtaining a normothermic 12 mmHg capnoperitoneum, a second 10 mm blunt tip balloon
5 trocar is inserted under direct vision and explorative laparoscopy is performed. Only if needed, careful
6 adhesiolysis may be performed to create sufficient working space. In case of an iatrogenic bowel lesion,
7 the procedure is ended after closure of the lesion, and ePIPAC-OX may be postponed by two to four
8 weeks. If the procedure is considered feasible, leucovorin (20 mg/m² BSA in 10 minutes) and bolus 5-
9 fluorouracil (400 mg/m² BSA in 15 minutes) are administered intravenously. In the meantime, ascites
10 (or injected saline if ascites is not present) is completely evacuated, sent for cytology and translational
11 research, and the ascites volume is documented. The Zühlke score and the peritoneal cancer index
12 (PCI) are registered and photographs are taken throughout the peritoneal cavity.[49,50] A piece of
13 normal peritoneum and three peritoneal metastases, preferably from different areas, are biopsied,
14 sent for histopathology and translational research, and their locations are documented and marked
15 with clips to enable biopsies of the same locations during subsequent procedures.

16 Then, the ePIPAC setup is installed. A stainless steel brush electrode (Ionwand[®], Alesi Surgical,
17 Cardiff, United Kingdom) is inserted through a mini-trocar under direct vision, secured with its tip at
18 least 2 cm away from other structures, and connected to its generator (Ultravision[®], Alesi Surgical,
19 Cardiff, United Kingdom). A nebuliser (CapnoPen[®], Capnomed GmbH, Villingendorf, Germany) is
20 inserted through one of the trocars and secured with its nozzle just inside the peritoneal cavity at a
21 safe distance from visceral organs. The camera, inserted through the other trocar, is secured by a
22 laparoscope holder in a way it permanently visualises the electrode and the nebuliser. The valve of the
23 trocar connected to the CO₂ insufflation remains opened, whereas the other trocar is connected to a
24 closed aerosol waste system (CAWS) with its valve closed. The CAWS consecutively consists of a smoke
25 evacuation filter, a water seal drainage system, an infant-paediatric electrostatic microparticle filter,
26 and the air waste system of the hospital. The preoperatively prepared syringe with oxaliplatin (92
27 mg/m² BSA diluted in a total volume of 150 ml 5% dextrose) is vented, placed in a standard
28 angiographic injector, and connected to the nebuliser with a saline-flushed high-pressure line
29 protected by a plastic camera cover. A leak-free capnoperitoneum is ensured by zero-flow of CO₂. If
30 necessary, incisions may be additionally sutured and Luer lock caps may be placed on balloon valves
31 of trocars. The angiographic injector is installed at a flow rate of 30 ml/min and a maximum pressure
32 of 200 pounds per square inch. Protective films are placed on the floor below the angiographic injector
33 and around the patient. The angiographic injector is positioned above a chemotherapy waste bin. The
34 peripheral venous line of the patient is connected to a 60 ml saline-containing syringe outside the
35 operating room. Vital parameters of the patient, real-time videolaparoscopy, and a patient-aimed

1
2
3 1 camera are displayed on three screens outside the operating room. The screen of the angiographic
4
5 2 injector is positioned in front of the window of the operating room. General anaesthesia is ensured for
6
7 3 at least another 40 minutes. A checklist is used to confirm that all aforementioned steps have been
8
9 4 adequately taken. After completion of the checklist, the entire operating personnel leaves the
10
11 5 operating room.

12 6 Oxaliplatin is injected through the nebuliser by remote controlled activation of the
13
14 7 angiographic injector from outside the operating room. After complete formation of the oxaliplatin-
15
16 8 containing aerosol in 5 minutes, the surgeon enters the operating room and turns on the Ultravision®
17
18 9 generator, which results in electrostatic precipitation of the aerosol. The electrostatic field and the
19
20 10 capnoperitoneum are maintained for another 25 minutes. During this phase, the patient and the
21
22 11 procedure are monitored through the three screens and the window of the operating room. Drugs
23
24 12 may be administered to the patient through the intravenous access outside the operating room if
25
26 13 necessary.

27 14 After 25 minutes, the surgeon enters the operating room, turns off the Ultravision®
28
29 15 generator, closes the trocar valve connected to the CO₂ insufflation, and opens the trocar valve
30
31 16 connected to the CAWS. After complete evacuation of the aerosol, the electrode and the nebuliser are
32
33 17 removed, the entire operating personnel enters the operating room, and a new capnoperitoneum is
34
35 18 obtained. Ascites and peritoneal biopsies are collected for pharmacokinetic purposes. In case no
36
37 19 bleeding or perforations are observed, instruments are removed and incisions are closed with
38
39 20 absorbable sutures. All instruments and materials are directly disposed in chemotherapy waste bins
40
41 21 and the operating room is cleaned according to existing HIPEC protocols.

42 22 After ePIPAC-OX, patients are admitted to the general surgical ward. To relieve postoperative
43
44 23 pain, patients receive paracetamol (1 g, four times daily), on-demand morphine, and 1 g of metamizole
45
46 24 directly after the procedure. To minimise postoperative nausea and vomiting, patients receive
47
48 25 perioperative dexamethasone and on-demand granisetron (1 mg, three times daily). Standard post-
49
50 26 surgical clinical evaluations are performed a few hours after the procedure and on every postoperative
51
52 27 day. Blood is drawn for bone marrow, liver, and kidney functions, albumin, and C-reactive protein on
53
54 28 every postoperative day. If the postoperative period is uneventful, patients are discharged on the first
55
56 29 postoperative day. All body excretes are considered oxaliplatin-contaminated for up to five days after
57
58 30 the procedure.

59 31 Dose reduction, prohibited and permitted concomitant care, and strategies to improve
60
32 adherence are not specified *a priori*, but left to the discretion of the treating physician. ePIPAC-OX is
33 repeated until clinical, radiological, or macroscopic (i.e. ascites, PCI) progression, unacceptable toxicity,
34 physician's decision to discontinue, or at patient's request to discontinue. In patients who develop

1 systemic metastases, continuation of ePIPAC-OX can only be considered if the patient has no systemic
2 palliative treatment options and stable peritoneal disease.

3 4 Outpatient evaluations

5 One week after each ePIPAC-OX, patients undergo clinical evaluation by phone. Four weeks after each
6 ePIPAC-OX, patients undergo radiological evaluation (i.e. thoracoabdominal CT, diffusion-weighted
7 magnetic resonance imaging [DW-MRI]), biochemical evaluation (i.e. bone marrow, liver, and kidney
8 functions, albumin, C-reactive protein, tumour markers), and clinical evaluation.

9 10 Questionnaires

11 Patients are asked to complete EQ-5D-5L, QLQ-C30, and QLQ-CR29 at baseline and one and four weeks
12 after each ePIPAC-OX.[51-53] iMTA Productivity Cost Questionnaire (PCQ) and iMTA Medical
13 Consumption Questionnaire (MCQ) are sent to the patients at baseline and four weeks after each
14 ePIPAC-OX (PCQ) and each second ePIPAC-OX (MCQ).[54,55]

15 16 Pharmacokinetics

17 Blood is collected during and after the first three procedures in each patient. Four ml of whole blood
18 is drawn and collected in heparin tubes before ePIPAC-OX and at 5, 10, 20, 30, 60, 120, 240, 360, and
19 1080 minutes after injection of oxaliplatin. After immediate centrifuging, an aliquot of plasma is stored
20 at -80°C until analysis. Another aliquot of 1 ml of plasma is centrifuged through an ultrafiltration
21 membrane and stored at -80°C until analysis. Urine, ascites, peritoneal metastases, and normal
22 peritoneum are collected during and after all procedures. Four ml of urine is collected in urinalysis
23 tubes before ePIPAC-OX and on the first postoperative day. These are stored at -20°C until analysis.
24 After discharge, patients are asked to collect four ml of urine in urinalysis tubes on the third, fifth, and
25 seventh postoperative day, and to store these specimens at their home address at -20°C until analysis.
26 After electrostatic precipitation of the aerosol, the surgeon aspirates a few ml of ascites and biopsies
27 two peritoneal metastases and two pieces of normal peritoneum, preferably from different locations.
28 These are collected in aliquots and directly stored at -80°C until analysis. Concentrations of oxaliplatin
29 are measured by using atomic absorption spectrophotometry.

30 31 Translational research

32 Before each ePIPAC-OX, 20 ml of blood is drawn and collected in 10 ml Cell-free DNA BCT tubes (Streck,
33 La Vista, NE, USA). According to the manufacturer's instructions, these tubes are sent to a central lab
34 for isolation and storage (-80°C) of plasma and cell pellet. Collected ascites or saline is centrifuged
35 twice (5 minutes, 420 g, zero break) under sterile conditions. The supernatant is snap frozen and stored

1
2
3 1 at -80°C for further analysis on soluble components. The cell pellet is suspended in organoid culture
4
5 2 medium at 4°C for transport and further work up. Of each collected PM, three parts are snap frozen
6
7 3 and stored at -80°C for sequencing analysis.
8
9 4

10 5 **Outcomes**

11 6 An assessment schedule is presented in *Table 1*. The primary outcome is the number of patients with
12
13 7 major toxicity, defined as grade ≥ 3 according to the Common Terminology Criteria for Adverse Events
14
15 8 (CTCAE) v4.0,[56] up to four weeks after the last ePIPAC-OX. Secondary outcomes are:
16
17 9

- 18 10 ▪ the environmental safety of ePIPAC-OX, based on air and surface concentrations of oxaliplatin
19 11 during the first three procedures, measured by atomic absorption spectrophotometry;
- 20 12 ▪ procedure-related characteristics of ePIPAC-OX (e.g. intraoperative complications, amount of
21 13 adhesions, technical difficulties, operating time);
- 22 14 ▪ the number of procedures in each patient and reasons for discontinuation;
- 23 15 ▪ minor toxicity, defined as grade ≤ 2 according to CTCAE v4.0,[56] up to four weeks after the last
24 16 ePIPAC-OX;
- 25 17 ▪ organ-specific toxicity, based on bone marrow, liver, and kidney functions measured at
26 18 different time points (Table 1);
- 27 19 ▪ major and minor postoperative complications, defined as grade ≥ 3 and grade ≤ 2 according to
28 20 Clavien-Dindo,[57] respectively, up to four weeks after the last ePIPAC-OX;
- 29 21 ▪ hospital stay, defined as the number of days between ePIPAC-OX and initial discharge;
- 30 22 ▪ readmissions, defined as any hospital admission after initial discharge, up to four weeks after
31 23 the last ePIPAC-OX;
- 32 24 ▪ radiological tumour response, based on central review of thoracoabdominal CT and DW-MRI
33 25 at baseline and four weeks after each ePIPAC-OX, performed by two independent radiologists
34 26 (JN, MLH) blinded to clinical outcomes (classification is not defined *a priori*);
- 35 27 ▪ histopathological tumour response, based on central review of collected peritoneal biopsies
36 28 during each ePIPAC-OX, performed by two independent pathologists (e.g. CJRH) blinded to
37 29 clinical outcomes by using the Peritoneal Regression Grading Score;[58]
- 38 30 ▪ macroscopic tumour response, based on PCI and ascites volume during each ePIPAC-OX;
- 39 31 ▪ biochemical tumour response, based on tumour markers measured at different time points
40 32 (Table 1);
- 41 33 ▪ cytological tumour response, based on collected ascites or peritoneal washing cytology during
42 34 each ePIPAC-OX;

- 1 ▪ quality of life, extracted from questionnaires (EQ-5D-5L, QLQ-C30, QLQ-CR29) at different time
- 2 points (Table 1);
- 3 ▪ costs, derived from the Dutch costing guidelines for health care research at the time of
- 4 analysis, based on case report forms, hospital information systems, and questionnaires (iMTA
- 5 PCQ, iMTA MCQ) at different time points (Table 1);
- 6 ▪ progression-free survival, defined as the time between enrolment and clinical, radiological, or
- 7 macroscopic progression, or death;
- 8 ▪ overall survival, defined as the time between enrolment and death;
- 9 ▪ the pharmacokinetics of oxaliplatin during and after ePIPAC-OX.

11 **Sample size**

12 Given the absence of evident clinical endpoint in this patient category, the investigators pragmatically
13 determined the sample size of this exploratory study. The investigators agreed that 60 procedures are
14 required to explore the feasibility, safety, tolerability, and preliminary efficacy of repetitive ePIPAC-OX
15 in this setting. Since the expected mean number of procedures is three per patient,[36] the initial
16 sample size is determined at 20 patients. This pragmatically determined sample size is approved by
17 the central ethics committee. Enrolled patients who do not undergo a first ePIPAC-OX (e.g. systemic
18 metastases on baseline radiology, non-access, resectable disease) are replaced to enrol 20 patients
19 who receive at least one ePIPAC-OX.

21 **Recruitment**

22 The study started in October 2017 and is currently enrolling patients. The investigators anticipate that
23 20 patients will be enrolled within a maximum of three years. Strategies for achieving adequate
24 participant enrolment are not defined *a priori*.

26 **Data collection and data management**

27 Outcomes are collected in all patients who receive at least one ePIPAC-OX. All baseline characteristics
28 and clinical outcomes are prospectively collected and entered in an ISO 27001 certified central study
29 database (De Research Manager, Deventer, Netherlands) with study-specific electronic case report
30 forms by a local investigator in each study centre (RJL, ECEW). This ISO 27001 certified system ensures
31 adequate data integrity, including data coding, security, and storage. Questionnaires (quality of life,
32 costs), peritoneal biopsies (histopathological response), and radiological examinations (radiological
33 response) are collected by the coordinating investigator (KPR) throughout the study and centrally
34 analysed after study completion. Plans to promote data quality, participant retention, and complete
35 follow-up are not specified *a priori*.

1 2 3 1 4 5 2 **Statistical methods**

6 3 Repetitive continuous outcomes (e.g. organ toxicity, quality of life, operating time) are analysed by
7 4 using the Wilcoxon signed-rank test, the paired samples t-test, the Friedman test, or repeated
8 5 measurements analysis of variance where appropriate. Repetitive categorical outcomes (e.g.
9 6 intraoperative complications, postoperative complications) are analysed by using the McNemar test,
10 7 the Wilcoxon signed-rank test, the Cochran's Q test, or generalised estimating equations where
11 8 appropriate. Time-to-event variables (i.e. overall and progression-free survival) are analysed and
12 9 displayed by using the Kaplan-Meier method. Other outcomes are analysed by using descriptive
13 10 statistics. All statistical tests are two-sided and $p < 0.05$ is considered statistically significant.
14
15
16
17
18
19
20
21

22 12 **Data monitoring**

23 13 Interim analyses are performed after 8 and 20 procedures. The study is terminated after these interim
24 14 analyses if CTCAE grade ≥ 3 toxicity, directly related to ePIPAC-OX, is observed after ≥ 4 and ≥ 10
25 15 procedures. Furthermore, the study is directly terminated if more than one CTCAE grade 5 toxicity,
26 16 directly related to ePIPAC-OX, occurs during the study. The coordinating investigator and the principal
27 17 investigator (IHJTH) have access to these interim results. The principal investigator makes the decision
28 18 to terminate or continue the study. The investigators decided that a data monitoring committee is not
29 19 needed given the clear stopping rules and the low expected toxicity of repetitive ePIPAC-OX.
30
31
32
33
34
35
36
37

38 21 **Harms**

39 22 Local investigators report all serious adverse events (SAEs) or suspected unexpected serious adverse
40 23 reactions (SUSARs) to the coordinating investigator within 24 hours. The coordinating investigator
41 24 reports SAEs/SUSARs to the ethics committee within seven days of first knowledge for lethal or life
42 25 threatening SAEs/SUSARs, and within fifteen days for other SAEs/SUSARs. The time window for
43 26 reporting SAEs/SUSARs is from enrolment up to four weeks after the last ePIPAC-OX.
44
45
46
47
48
49

50 28 **Auditing**

51 29 The study is audited by independent qualified monitors of Clinical Trial Centre Maastricht (Maastricht,
52 30 Netherlands) as a high-risk study according to the brochure 'Kwaliteitsborging mensgebonden
53 31 onderzoek 2.0' by the Dutch Federation of University Medical Centres. This means that study centres
54 32 are audited at least three times per year, depending on enrolment, with 100% auditing of the study
55 33 master file, investigator site files, informed consent forms, eligibility criteria, source data verification,
56 34 and SAEs/SUSARs.
57
58
59
60

1 **Patient and public involvement**

2 Patients were not involved in the study design before the start of the study. Shortly after the start of
3 the study, the investigators presented the study design to a patient advisory group. Major topics of
4 discussion were the rationale for the study, outcome parameters, recruitment strategies, the patient
5 information sheet, dissemination strategies, and the potential risks, benefits, and burden of
6 participation from the patient's perspective. The patient advisory group supported the presented
7 study design. Although the patient advisory group is not involved in the recruitment and the conduct
8 of the study, they will be involved in plans to disseminate the study results to relevant patient groups.

10 **ETHICS AND DISSEMINATION**

11 **Research ethics approval**

12 This study is approved by an ethics committee (MEC-U, Nieuwegein, Netherlands, number R17.038),
13 the Dutch competent authority, and the institutional review boards of both study centres.

15 **Protocol amendments**

16 Important protocol modifications are communicated to the ethics committee, the Dutch competent
17 authority, the institutional review boards of both study centres, all investigators, and trial registries.

19 **Consent or assent**

20 Written informed consent is obtained by local investigators at the outpatient clinic of the study
21 centres. Patients are given the possibility to give separate permission for undergoing DW-MRI and for
22 storage of specimens for translational research.

24 **Confidentiality**

25 Personal information about potential and enrolled patients is collected, shared, and maintained
26 according to the Dutch law (Wet Bescherming Persoonsgegevens).

28 **Declaration of interests**

29 The investigators declare no competing interests. The funders have no role in the study design, in
30 writing the report, or in the decision to submit the report for publication.

32 **Access to data**

33 All investigators have access to the final datasets, without contractual agreements that limit such
34 access.

1 **Ancillary and post-study care**

2 The sponsor (Catharina Hospital, Eindhoven, Netherlands) is insured to provide cover for patients who
3 suffer harm from study participation. After discontinuation of ePIPAC-OX, patients receive standard
4 palliative treatment for unresectable metastatic colorectal cancer according to Dutch guidelines.[4]

6 **Dissemination policy**

7 Results of the study are personally communicated to participants and intended for publication in peer-
8 reviewed medical journals and for presentation to patients, healthcare professionals, and other
9 stakeholders. Authorship eligibility guidelines for the main manuscript and manuscript of side studies
10 are not defined *a priori*. The full protocol and Dutch informed consent forms are, or will become,
11 available upon reasonable request.

13 **REFERENCES**

- 14 [1] van Gestel YR, de Hingh IH, van Herk-Sukel MP, et al. Patterns of metachronous metastases after
15 curative treatment of colorectal cancer. *Cancer Epidemiol* 2014;38:448-54.
- 16 [2] van der Geest LG, Lam-Boer J, Koopman M, et al. Nationwide trends in incidence, treatment and
17 survival of colorectal cancer patients with synchronous metastases. *Clin Exp Metastasis* 2015;32:457-
18 65.
- 19 [3] Razenberg LG, Lemmens VE, Verwaal VJ, et al. Challenging the dogma of colorectal peritoneal
20 metastases as an untreatable condition: results of a population-based study. *Eur J Cancer* 2016;65:113-
21 20.
- 22 [4] Landelijke werkgroep Gastro Intestinale Tumoren. Richtlijn colorectaal carcinoom. 2014.
23 <https://www.oncoline.nl/colorectaalcarcinoom>. Accessed 10 Dec 2018.
- 24 [5] Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer
25 given systemic therapy: an analysis of individual patient data from prospective randomised trials from
26 the Analysis and Research in Cancers of the Digestive System (ARCAD) database. *Lancet Oncol*
27 2016;17:1709-19.
- 28 [6] Sugarbaker PH, Stuart OA, Vidal-Jove J, et al. Pharmacokinetics of the peritoneal-plasma barrier
29 after systemic mitomycin C administration. *Cancer Treat Res* 1996;82:41-52.
- 30 [7] Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug
31 administration in the treatment of ovarian cancer. *Cancer Treat Rep* 1978;62:1-11.
- 32 [8] Jacquet P, Sugarbaker PH. Peritoneal-plasma-barrier. *Cancer Treat Res* 1996;82:53-63.
- 33 [9] Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue
34 penetration and surface exposure. *J Natl Cancer Inst* 1997;89:480-7.

- 1
2
3 1 [10] Markman M. Limited use of the intraperitoneal route for ovarian cancer – why? *Nat Rev Clin Oncol*
4 2015;12:628-30.
- 5 2
6 3 [11] Solass W, Hetzel A, Schwarz T, et al. PIPAC Technology. In: Reymond MA, Solass W. Pressurized
7 4 IntraPeritoneal Aerosol Chemotherapy – Cancer under Pressure. De Gruyter, 2014.
- 8 5
9 6 [12] Reymond MA, Hu B, Garcia A, et al. Feasibility of therapeutic pneumoperitoneum in a large animal
10 7 model using a microvaporisator. *Surg Endosc* 2000;14:51-5.
- 11 8
12 9 [13] Jacquet P, Stuart OA, Chang D, et al. Effects of intra-abdominal pressure on pharmacokinetics and
13 10 tissue distribution of doxorubicin after intraperitoneal administration. *Anticancer Drugs* 1996;7:596-
14 11 603.
- 15 12
16 13 [14] Esquis P, Consolo D, Magnin G, et al. High intra-abdominal pressure enhances the penetration and
17 14 antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. *Ann Surg*
18 15 2006;244:106-12.
- 19 16
20 17 [15] Solass W, Herbette A, Schwarz T, et al. Therapeutic approach of human peritoneal carcinomatosis
21 18 with Dbait in combination with capnoperitoneum: proof of concept. *Surg Endosc* 2012;26:847-52.
- 22 19
23 20 [16] Solass W, Hetzel A, Nadiradze G, et al. Description of a novel approach for intraperitoneal drug
24 21 delivery and the related device. *Surg Endosc* 2012;26:1849-55.
- 25 22
26 23 [17] Facy O, Al Samman S, Magnin G, et al. High pressure enhances the effect of hyperthermia in
27 24 intraperitoneal chemotherapy with oxaliplatin: an experimental study. *Ann Surg* 2012;256:1084-8.
- 28 25
29 26 [18] Solass W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis
30 27 using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. *Ann Surg Oncol*
31 28 2014;21:553-9.
- 32 29
33 30 [19] Blanco A, Giger-Pabst U, Solass W, et al. Renal and hepatic toxicities after pressurized
34 31 intraperitoneal aerosol chemotherapy (PIPAC). *Ann Surg Oncol* 2013;20:2311-6.
- 35 32
36 33 [20] Eveno C, Haidara A, Ali I, et al. Experimental pharmacokinetics evaluation of chemotherapy
37 34 delivery by PIPAC for colon cancer: first evidence for efficacy. *Pleura and Peritoneum* 2017;2:103-109.
- 38 35
39 36 [21] Grass F, Vuagnieaux A, Teixeira-Farinha H, et al. Systematic review of pressurized intraperitoneal
40 37 aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. *Br J Surg*
41 38 2017;104:669-78.
- 42 39
43 40 [22] Tempfer C, Giger-Pabst U, Hilal Z, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
44 41 for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special
45 42 emphasis on ovarian cancer. *Arch Gynecol Obstet* 2018;298:243-57.
- 46 43
47 44 [23] Nowacki M, Alyami M, Villeneuve L, et al. Multicenter comprehensive methodological and
48 45 technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions
49 46 performed in 349 patients for peritoneal carcinomatosis treatment: an international survey study. *Eur*
50 47 *J Surg Oncol* 2018;44:991-6.
- 51 48
52 49
53 50
54 51
55 52
56 53
57 54
58 55
59 56
60 57

- 1
2
3 1 [24] Willaert W, Sessink P, Ceelen W. Occupational safety of pressurized intraperitoneal aerosol
4 2 chemotherapy (PIPAC). *Pleura and Peritoneum* 2017;2:121-8.
- 5 3 [25] Graversen M, Lundell L, Fristrup C, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
6 4 as an outpatient procedure. *Pleura and Peritoneum* 2018;20180128.
- 7 5 [26] Kakchekeeva T, Demtröder C, Herath NI, et al. In vivo feasibility of electrostatic precipitation as an
8 6 adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC). *Ann Surg Oncol* 2016;23(Suppl
9 7 5):592-8.
- 10 8 [27] Odendahl K, Solass W, Demtröder C, et al. Quality of life of patients with end-stage peritoneal
11 9 metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). *Eur J Surg Oncol*
12 10 2015;41:1379-85.
- 13 11 [28] Robella M, Vaira M, de Simone M. Safety and feasibility of pressurized intraperitoneal aerosol
14 12 chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat
15 13 peritoneal carcinomatosis. *World J Surg Oncol* 2016;14:128.
- 16 14 [29] Teixeira Farinha H, Grass F, Kefleyesus A, et al. Impact of pressurized intraperitoneal aerosol
17 15 chemotherapy on quality of life and symptoms in patients with peritoneal carcinomatosis: a
18 16 retrospective cohort study. *Gastroenterol Res Pract* 2017;2017:4596176.
- 19 17 [30] Hübner M, Teixeira Farinha H, Grass F, et al. Feasibility and safety of pressurized intraperitoneal
20 18 aerosol chemotherapy for peritoneal carcinomatosis: a retrospective cohort study. *Gastroenterol Res*
21 19 *Pract* 2017;2017:6852749.
- 22 20 [31] Hübner M, Grass F, Teixeira-Farinha H, et al. Pressurized intraperitoneal aerosol chemotherapy –
23 21 practical aspects. *Eur J Surg Oncol* 2017;43:1102-9.
- 24 22 [32] Alyami M, Gagniere J, Sgarbura O, et al. Multicentric initial experience with the use of the
25 23 pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable
26 24 peritoneal carcinomatosis. *Eur J Surg Oncol* 2017;43:2178-83.
- 27 25 [33] Graversen M, Detlefsen S, Bjerregaard JK, et al. Prospective, single-center implementation and
28 26 response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal
29 27 metastasis. *Ther Adv Med Oncol* 2018;10:1758835918777036.
- 30 28 [34] Kurtz F, Struller F, Horvath P, et al. Feasibility, safety, and efficacy of pressurized intraperitoneal
31 29 aerosol chemotherapy (PIPAC) for peritoneal metastasis: a registry study. *Gastroenterol Res Pract*
32 30 2018;2018:2743985.
- 33 31 [35] Teixeira Farinha H, Grass F, Labgaa I, et al. Inflammatory response and toxicity after pressurized
34 32 intraperitoneal aerosol chemotherapy. *J Cancer* 2018;9:13-20.
- 35 33 [36] Demtröder C, Solass W, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy with
36 34 oxaliplatin in colorectal peritoneal metastasis. *Colorectal Dis* 2016;18:364-71.

- 1
2
3 1 [37] Graversen M, Detlefsen S, Pfeiffer P, et al. Severe peritoneal sclerosis after repeated pressurized
4 2 intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature
5 3 survey. *Clin Exp Metastasis* 2018;35:103-8.
- 6 4 [38] Siebert M, Alyami M, Mercier F, et al. Severe hypersensitivity reactions to platinum compounds
7 5 post-pressurized intraperitoneal aerosol chemotherapy (PIPAC): first literature report. *Cancer*
8 6 *Chemother Pharmacol* Published Online First: 3 Dec 2018. doi: 10.1007/s00280-018-3740-3.
- 9 7 [39] Clinicaltrials.gov. www.clinicaltrials.gov. Accessed 10 Dec 2018.
- 10 8 [40] Solass W, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC):
11 9 occupational health and safety aspects. *Ann Surg Oncol* 2013;20:3504-11.
- 12 10 [41] Graversen M, Pedersen PB, Mortensen MB. Environmental safety during the administration of
13 11 Pressurized intraperitoneal aerosol chemotherapy (PIPAC). *Pleura and Peritoneum* 2016;1:203-8.
- 14 12 [42] Ndaw S, Hanser O, Kenepekian V, et al. Occupational exposure to platinum drugs during
15 13 intraperitoneal chemotherapy. Biomonitoring and surface contamination. *Toxicol Lett* 2018;298:171-
16 14 6.
- 17 15 [43] Ametsbichler P, Böhlant A, Nowak D, et al. Occupational exposure to cisplatin/oxaliplatin during
18 16 pressurized intraperitoneal aerosol chemotherapy (PIPAC)? *Eur J Surg Oncol* 2018;44:1793-9.
- 19 17 [44] Dumont F, Senellart H, Pein F, et al. Phase I/II study of oxaliplatin dose escalation via a laparoscopic
20 18 approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable
21 19 peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): rationale and design.
22 20 *Pleura and Peritoneum* 2018;20180120
- 23 21 [45] Kim G, Tan HL, Chen E, et al. Study protocol: phase 1 dose escalating study of pressurized
24 22 intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis. *Pleura and*
25 23 *Peritoneum* 2018;20180118.
- 26 24 [46] Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after
27 25 complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. *Ann Oncol*
28 26 2002;13:267-72.
- 29 27 [47] Giachetti S, Perpoint B, Zidani R, et al. Phase III multicentre randomized trial of oxaliplatin added
30 28 to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. *J*
31 29 *Clin Oncol* 2000;18:136-47.
- 32 30 [48] Giger-Pabst U, Tempfer CB. How to perform safe and technically optimized pressurized
33 31 intraperitoneal aerosol chemotherapy (PIPAC): experience after a consecutive series of 1200
34 32 procedures. *J Gastrointest Surg* 2018;22:2187-93.
- 35 33 [49] Zühlke HV, Lorenz EM, Straub EM, et al. Pathophysiology and classification of adhesions.
36 34 *Langenbecks Arch Chir II Verh Dtsch Ges Chir* 1990:1009-16.

- 1
2
3 1 [50] Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients
4 with peritoneal carcinomatosis. *Cancer Treat Res* 1996;82:359-74.
- 5 2
6 3 [51] Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level
7 version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;20:1727-36.
- 8 4
9 5 [52] Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and
10 Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in
11 oncology. *J Natl Cancer Inst* 1993;85:365-76.
- 12 6
13 7 [53] Stiggelbout AM, Kunneman M, Baas-Thijssen MC, et al. The EORTC QLQ-CR29 quality of life
14 questionnaire for colorectal cancer: validation of the Dutch version. *Qual Life Res* 2016;25:1853-8.
- 15 8
16 9 [54] Bouwmans C, Krol M, Severens H, et al. The iMTA Productivity Cost Questionnaire: a standardized
17 instrument for measuring and valuing health-related productivity losses. *Value Health* 2015;18:753-8.
- 18 10
19 11 [55] iMTA: questionnaires. <https://www.imta.nl/questionnaires/>. Accessed 10 Dec 2018.
- 20 12
21 13 [56] Common Terminology Criteria for Adverse Events (CTCAE) v4.0. National Cancer Institute. 2009.
22 [https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-](https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf)
23 [29_QuickReference_8.5x11.pdf](https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf). Accessed 10 Dec 2018.
- 24 14
25 15 [57] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with
26 evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;240:205-13.
- 27 16
28 17 [58] Solass W, Sempoux C, Carr N, et al. Reproducibility of the Peritoneal Regression Grading Score
29 (PRGS) for assessment of response to therapy in peritoneal metastasis. *Histopathology* Published
30 Online First: 27 Jan 2019. doi:10.1111/his.13829.

31 32 33 34 35 36 37 38 22 **ACKNOWLEDGEMENTS**

39 None.
40
41
42
43

44 25 **AUTHORS' CONTRIBUTIONS**

45 26 KPR is the coordinating investigator. RJL, AMJT, GMC, JWAB, SWN are the local investigators of the first
46 study centre. ECEW, and TJMK, ML, MJW, and DB are the local investigators of the second study centre.
47 27 RT performs the pharmacokinetic analyses. MJD is the study pharmacologist supervising the
48 pharmacokinetic analyses. JN and MJL are the study radiologists performing the central radiological
49 28 review. CJRH is the study pathologist performing the central histopathological review. IE and RJAF are
50 29 responsible for translational research on blood. AC and OK are responsible for translational research
51 30 on ascites and PM. IHJTH is the principal investigator. KPR, RJL, and IHJTH made substantial
52 31 contributions to conception and design of the study, drafted the protocol, and drafted the manuscript.
53 32 The other authors made substantial contributions to conception and design of the study and critically
54 33
55 34
56
57
58
59
60

1 revised the protocol and the manuscript for important intellectual content. All authors gave final
2 approval of the version to be published and agree to be accountable for all aspects of the work.

3 4 **FUNDING**

5 This study is supported by Catharina Research Foundation (grant number: 2017-5) and St. Antonius
6 Research Foundation (grant number: 17.4).

7 8 **COMPETING INTERESTS**

9 None declared.

10 11 **ETHICAL APPROVAL**

12 This study is approved by an ethics committee (MEC-U, Nieuwegein, Netherlands, number R17.038),
13 the Dutch competent authority (CCMO, The Hague, Netherlands), and the institutional review boards
14 of both study centres.

15 16 **DATA SHARING**

17 Not applicable.

18 19 **PATIENT CONSENT**

20 Not applicable.

21 22 **PROTOCOL VERSION**

23 Version 6, 10 January 2019
24
25
26
27
28
29
30
31
32
33
34
35

1
2
3 **1 FIGURE TITLES**

4
5 **2 Figure 1.** Flow chart of the CRC-PIPAC study
6
7 **3**

8 **4 FIGURE LEGENDS**

9
10 **5** Figure 1. *ePIPAC-OX* electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin;

11 **6** **B** Bloods (organ toxicity, tumour markers)

12 **7** **c** Cytology (ascites or peritoneal washing with saline)


13 **8** **H** Histopathology (peritoneal biopsies)

14 **9** **P** Pharmacokinetics (blood, urine, ascites, PM, normal peritoneum)

15 **10** **Q** Questionnaires (quality of life, costs)

16 **11** **R** Radiology (thoracoabdominal CT, diffusion-weighted MRI)

17 **12** **T** Translational research (blood, ascites, PM)





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
	2b	All items from the World Health Organization Trial Registration Data Set	Entire manuscript
Protocol version	3	Date and version identifier	20
Funding	4	Sources and types of financial, material, and other support	20
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1-2, 19-20
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	14
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	Entire manuscript

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention **3-5**

4

5

6 6b Explanation for choice of comparators **Not applicable**

7

8 Objectives 7 Specific objectives or hypotheses **5**

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) **6**

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained **6**

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) **6**

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered **6-11**

23

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) **9**

26

27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) **9**

29

30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial **9**

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended **11-12**

35

36

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) **Table 1, Figure 1**

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	12
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	12
5				
6				
7	Methods: Assignment of interventions (for controlled trials)			
8	Allocation:			
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Not applicable
11	generation			
12				
13				
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	Not applicable
17	concealment			
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	Not applicable
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	Not applicable
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	Not applicable
28				
29				
30				
31	Methods: Data collection, management, and analysis			
32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	12
34	methods			
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	12
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	12
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	13
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	Not applicable
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	12
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	13
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	13
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	13
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	13
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	14
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	14
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	14
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	14
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	14
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	14
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	14
14				
15				
16				
17	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	15
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	15
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	15
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	15
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Available upon request
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	10
35				
36				

37 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.
 40

BMJ Open

Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC).

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030408.R1
Article Type:	Protocol
Date Submitted by the Author:	24-May-2019
Complete List of Authors:	Rovers, Koen; Catharina Hospital, Surgery Lurvink, Robin; Catharina Hospital, Surgery Wassenaar, Emma; Sint Antonius Hospital, Surgery Kootstra, Thomas; Sint Antonius Hospital, Surgery Scholten, Harm; Catharina Hospital, Anaesthesiology Tajzai, Rudaba; Catharina Hospital, Clinical Pharmacy Deenen, Maarten; Catharina Hospital, Clinical Pharmacy Nederend, Joost; Catharina Hospital, Radiology Lahaye, Max; Netherlands Cancer Institute, Radiology Huysentruyt, Clément; Catharina Hospital, Pathology van 't Erve, Iris; Netherlands Cancer Institute, Pathology Fijneman, Remond; Netherlands Cancer Institute, Pathology Constantinides, Alexander; UMC Utrecht, Imaging and Cancer Kranenburg, Onno; UMC Utrecht, Imaging and Cancer Los, Maartje; Sint Antonius Hospital, Medical Oncology Thijs, Annemarie; Catharina Hospital, Medical Oncology Creemers, Geert-Jan; Catharina Hospital, Medical Oncology Burger, Jacobus; Catharina Hospital, Surgery Wiezer, René; Sint Antonius Hospital, Surgery Boerma, Djamila ; Sint Antonius Hospital, Surgery Nienhuijs, Simon W.; Catharina Hospital, Surgery de Hingh, Ignace; Catharina Hospital, Surgery
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Gastroenterology and hepatology, Surgery
Keywords:	PIPAC, Peritoneal metastases, Colorectal cancer, Colorectal surgery < SURGERY, Gastrointestinal tumours < ONCOLOGY, Intraperitoneal chemotherapy

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Title

Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC).

Corresponding author

Prof. dr. I.H.J.T. (Ignace) de Hingh, MD, PhD;
Department of Surgery, Catharina Hospital;
PO Box 1350, 5602 ZA, Eindhoven, Netherlands;
E-mail: ignace.d.hingh@catharinaziekenhuis.nl;
Telephone: +31402397150.

Authors

Koen P. Rovers¹; Robin J. Lurvink¹; Emma C.E. Wassenaar²; Thomas J.M. Kootstra²; Harm J. Scholten³; Rudaba Tajzai^{1,4}; Maarten J. Deenen^{4,5}; Joost Nederend⁶; Max J. Lahaye⁷; Clément J.R. Huysentruyt⁸; Iris van 't Erve⁹; Remond J.A. Fijneman⁹; Alexander Constantinides¹⁰; Onno Kranenburg¹⁰; Maartje Los¹¹; Anna M.J. Thijs¹²; Geert-Jan M. Creemers¹²; Jacobus W.A. Burger¹; Marinus (René) J. Wiezer²; Djamila Boerma²; Simon W. Nienhuijs¹; Ignace H.J.T. de Hingh^{1,13}.

Affiliations

¹Department of Surgery, Catharina Hospital, Eindhoven, Netherlands;

²Department of Surgery, St. Antonius Hospital, Nieuwegein, Netherlands;

³Department of Anaesthesiology, Catharina Hospital, Eindhoven, Netherlands;

⁴Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, Netherlands;

⁵Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, Netherlands;

⁶Department of Radiology, Catharina Hospital, Eindhoven, Netherlands;

⁷Department of Radiology, Netherlands Cancer Institute, Amsterdam, Netherlands;

⁸Department of Pathology, Catharina Hospital, Eindhoven, Netherlands;

⁹Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands;

¹⁰Imaging and Cancer, Utrecht Platform for Organoid Technology, University Medical Centre Utrecht, Utrecht, Netherlands;

¹¹Department of Medical Oncology, St. Antonius Hospital, Nieuwegein, Netherlands;

¹²Department of Medical Oncology, Catharina Hospital, Eindhoven, Netherlands;

1
2
3 1 ¹³Grow – School for Oncology and Developmental Biology, Maastricht University, Maastricht,
4
5 2 Netherlands

6
7 3
8 4 **Word count**

9 5 3988.
10
11 6

12
13 7 **Abstract**

14 8 *Introduction:* Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy with
15 9 oxaliplatin (ePIPAC-OX) is offered as a palliative treatment option for patients with isolated
16 10 unresectable colorectal peritoneal metastases (PM) in several centres worldwide. However, little is
17 11 known about its feasibility, safety, tolerability, efficacy, costs, and pharmacokinetics in this setting. This
18 12 study aims to explore these parameters in patients with isolated unresectable colorectal PM who
19 13 receive repetitive ePIPAC-OX as a palliative monotherapy.

20 14 *Methods and analysis:* This multicentre, open-label, single-arm, phase II study is performed in two
21 15 Dutch tertiary referral hospitals for the surgical treatment of colorectal PM. Eligible patients are adults
22 16 who have histologically or cytologically proven isolated unresectable PM of a colorectal or appendiceal
23 17 carcinoma, a good performance status, adequate organ functions, and no symptoms of
24 18 gastrointestinal obstruction. Instead of standard palliative treatment, enrolled patients receive
25 19 laparoscopy-controlled ePIPAC-OX (92 mg/m² body-surface area [BSA]) with intravenous leucovorin
26 20 (20 mg/m² BSA) and bolus 5-fluorouracil (400 mg/m² BSA) every six weeks. Four weeks after each
27 21 procedure, patients undergo clinical, radiological, and biochemical evaluation. ePIPAC-OX is repeated
28 22 until disease progression, after which standard palliative treatment is (re)considered. The primary
29 23 outcome is the number of patients with major toxicity (grade ≥ 3 according to the Common
30 24 Terminology Criteria for Adverse Events v4.0) up to four weeks after the last ePIPAC-OX. Secondary
31 25 outcomes are the environmental safety of ePIPAC-OX, procedure-related characteristics, minor
32 26 toxicity, postoperative complications, hospital stay, readmissions, quality of life, costs,
33 27 pharmacokinetics of oxaliplatin, progression-free survival, overall survival, and the radiological,
34 28 histopathological, cytological, biochemical, and macroscopic tumour response.

35 29 *Ethics and dissemination:* This study is approved by an ethics committee, the Dutch competent
36 30 authority, and the institutional review boards of both study centres. Results are intended for
37 31 publication in peer-reviewed medical journals and for presentation to patients, healthcare
38 32 professionals, and other stakeholders.

39 33 *Registration:* ClinicalTrials.gov/NCT03246321, ISRCTN/ISRCTN89947480, NTR/NTR6603,
40 34 EudraCT/2017-000927-29.
41 35

1
2
3 1 Currently, pressurised intraperitoneal aerosol chemotherapy (PIPAC) is one of these systems that
4 2 internationally gains the most attention.
5
6 3

4 **Pressurised intraperitoneal aerosol chemotherapy (PIPAC)**

5 PIPAC is a laparoscopy-controlled repetitive intraperitoneal administration of low-dose chemotherapy
6 as a pressurised aerosol.[11,12] It combines the theoretical pharmacokinetic advantages of low-dose
7 intraperitoneal chemotherapy (i.e. low toxicity, high intraperitoneal concentration, low systemic
8 concentration) with the principles of an aerosol (homogeneous intraperitoneal distribution) and intra-
9 abdominal pressure (deep tissue penetration).[13-20] Two groups systematically reviewed results of
10 non-comparative clinical studies that assessed the feasibility, safety, tolerability, and preliminary
11 efficacy of PIPAC with various drugs for PM of various origins.[21,22] They concluded that PIPAC is a
12 safe, feasible, and well tolerated treatment with good preliminary response rates.[21,22] These
13 preliminary conclusions have led to an increasing acceptance of PIPAC as a palliative treatment option
14 for PM in several centres worldwide.[23] In these centres, patients with isolated unresectable
15 colorectal PM usually receive PIPAC with oxaliplatin (PIPAC-OX) in an empirically chosen dosage of 92
16 mg/m² body-surface area (BSA) every four to six weeks.[23] Some centres use electrostatic
17 precipitation of the aerosol during PIPAC-OX (ePIPAC-OX),[24,25] since this could increase tissue
18 penetration of oxaliplatin.[26]

20 **PIPAC for colorectal PM**

21 Several clinical studies included patients who received repetitive PIPAC-OX for colorectal PM.[27-36]
22 However, the vast majority of these studies reported outcomes of entire cohorts that received
23 repetitive PIPAC with various drugs for PM of various origins without presenting subgroup analyses of
24 patients who received PIPAC-OX for colorectal PM.[27-34] Only two studies reported separate
25 outcomes of repetitive PIPAC-OX for colorectal PM.[35,36] By using a prospectively maintained
26 database, Teixeira-Farinha *et al* retrospectively included 20 patients with isolated colorectal PM who
27 received 37 procedures.[35] They concluded that repetitive PIPAC-OX causes a modest and transitory
28 inflammatory response without haematological, renal, or hepatic toxicity.[35] Demtröder *et al.*
29 retrospectively included 17 patients with isolated colorectal PM who received 48 procedures within
30 an off-label program.[36] They concluded that repetitive PIPAC-OX induces regression of pretreated
31 colorectal PM and that the toxicity seems to be low.[36] Both studies have a retrospective design
32 without predefined eligibility criteria and endpoints. Moreover, both studies included patients who
33 received repetitive PIPAC-OX as a monotherapy as well as patients who received PIPAC-OX in
34 combination with palliative systemic therapy. These shortcomings strongly impede the interpretation

1 of these studies. Besides, recently published case reports suggested that PIPAC-OX could lead to severe
2 hypersensitivity reactions and peritoneal sclerosis.[37,38]

3 4 **Rationale for this study**

5 In conclusion, little is known about the safety, tolerability, and efficacy of repetitive PIPAC-OX in
6 patients with isolated unresectable colorectal PM, whereas nothing is known about its costs and
7 pharmacokinetics. Specifically for repetitive ePIPAC-OX, all these outcomes have never been reported.
8 This questions the current use of repetitive ePIPAC-OX as a palliative treatment option for isolated
9 unresectable colorectal PM outside the framework of clinical study protocols. Ideally, these patients
10 are included in prospective studies with predefined eligibility criteria, interventions, and endpoints.
11 However, by the knowledge of the investigators, such studies are currently lacking and not
12 ongoing.[39] Therefore, this study aims to prospectively explore the safety, tolerability, preliminary
13 efficacy, costs, and pharmacokinetics of repetitive ePIPAC-OX as a palliative treatment for isolated
14 unresectable colorectal PM. Although implementation of PIPAC appears feasible and occupationally
15 safe,[21,22,24,40-43] there is no experience with PIPAC in the Netherlands. Hence, this study also aims
16 to assess the feasibility of implementation of ePIPAC-OX in two Dutch tertiary referral hospitals for the
17 surgical treatment of colorectal PM.

18 19 **Rationale for intervention**

20 Repetitive ePIPAC-OX may be administered as part of a bidirectional therapy with palliative systemic
21 therapy or as a monotherapy. The bidirectional therapy hypothetically maximises tumour response,
22 probably at the cost of an increased treatment burden that could interfere with quality of life.
23 Repetitive ePIPAC-OX as a monotherapy hypothetically temporarily stabilises the intraperitoneal
24 disease burden with minimal toxicity and preservation of quality of life. For this study, the investigators
25 decided to administer repetitive ePIPAC-OX as a palliative monotherapy with (re)consideration of
26 standard palliative treatment upon progression. According to internationally used protocols, ePIPAC-
27 OX is administered in a dosage of 92 mg/m² at six-weekly intervals.[23] The investigators actively
28 followed two ongoing phase I studies in which repetitive PIPAC-OX is administered in various pre-
29 planned dosage levels to evaluate whether the dosage of oxaliplatin in this study needs to be
30 modified.[44,45] Before administration of ePIPAC-OX, patients receive intravenous low-dose
31 leucovorin with bolus 5-fluorouracil, since this is thought to potentiate the effect of intraperitoneal
32 oxaliplatin.[46,47]

33 34 **METHODS AND ANALYSIS**

35 **Design and setting**

1
2
3 1 This prospective, open-label, single-arm, phase II study is performed in two Dutch teaching hospitals
4 2 qualified as tertiary referral hospitals for the surgical treatment of colorectal PM.
5
6 3
7

8 4 **Eligibility criteria**

9 5 Eligible patients are adults who have:

- 10 6
- 11 7 ▪ a World Health Organisation (WHO) performance status of ≤ 1 ;
 - 12 8 ▪ histological or cytological proof of PM of a colorectal or appendiceal carcinoma;
 - 13 9 ▪ unresectable disease determined by the treating physician, based on abdominal computed
14 10 tomography (CT) and a diagnostic laparoscopy or laparotomy;
 - 15 11 ▪ adequate organ functions (haemoglobin ≥ 5.0 mmol/L, neutrophils $\geq 1.5 \times 10^9$ /L, platelets ≥ 100
16 12 $\times 10^9$ /L, serum creatinine $< 1.5 \times$ upper limit of normal [ULN], creatinine clearance ≥ 30 ml/min,
17 13 and liver transaminases $< 5 \times$ ULN);
 - 18 14 ▪ no symptoms of gastrointestinal obstruction;
 - 19 15 ▪ no radiological evidence of systemic metastases;
 - 20 16 ▪ no contraindications for oxaliplatin or 5-fluorouracil/leucovorin;
 - 21 17 ▪ no contraindications for a laparoscopy;
 - 22 18 ▪ no previous PIPAC-procedures.
- 23
24
25
26
27
28
29
30
31
32
33
34

35 20 Importantly, enrolment is allowed for patients with an unresected primary tumour (if asymptomatic)
36 21 and for patients in various lines of palliative treatment, including patients who refuse, have not had,
37 22 or do not qualify for first-line palliative systemic therapy. All potentially eligible patients are discussed
38 23 by a multidisciplinary team. Enrolled patients are informed about the potential consequences of
39 24 postponing or discontinuing standard palliative treatment by a medical oncologist prior to enrolment.
40
41
42
43
44

45 26 **Interventions and procedures**

46 27 *Figure 1* shows a flow chart of the study. *Table 1* presents a schedule of enrolment, interventions, and
47 28 assessments.
48
49

50 29
51 30
52 31
53 32
54 33
55 34
56 35
57
58
59
60

Table 1. Schedule of enrolment, interventions, and assessments.

	Study period				
	Enrolment/allocation	Post-enrolment			
		Outpatient clinics	Baseline radiology	Each ePIPAC-OX	1 week after each ePIPAC-OX
ENROLMENT/ALLOCATION					
Eligibility screen	X				
Informed consent	X				
INTERVENTIONS					
ePIPAC-OX			X		
Blood (organ functions, tumour markers)	X		X ^A		X
Pharmacokinetics (blood, urine, ascites, PM, normal peritoneum) ^B			X		
Translational research (blood, ascites, PM)			X ^C		
Thoracoabdominal computed tomography		X			X
Diffusion-weighted magnetic resonance imaging		X			X
Cytology (ascites or peritoneal washing)			X		
Histopathology (peritoneal biopsies)			X		
Questionnaires: quality of life		X		X	X
Questionnaires: costs ^D		X			X
ASSESSMENTS					
Baseline characteristics	X	X	X		
Toxicity			X	X	X
Environmental safety of ePIPAC-OX ^E			X		
Procedure-related characteristics			X		
Number of procedures in each patient, reasons for discontinuation			X	X	X
Postoperative complications			X	X	X
Hospital stay			X		
Readmissions				X	X
Clinical evaluation			X	X	X
Radiological tumour response		X			X
Histopathological tumour response			X		
Cytological tumour response			X		
Macroscopic tumour response			X		
Biochemical tumour response			X		X
Quality of life		X		X	X
Costs		X			X
Progression-free survival			X	X	X
Overall survival			X	X	X
ePIPAC-OX electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin; PM peritoneal metastases; ^A drawn on each postoperative day; ^B blood is drawn before ePIPAC-OX and at 5, 10, 20, 30, 60, 120, 240, 360, and 1080 minutes after oxaliplatin injection during/after the first three procedures, urine is collected before ePIPAC-OX and on postoperative days 1, 3, 5, and 7, ascites/PM/normal peritoneum are collected directly after oxaliplatin injection; ^C blood is drawn before ePIPAC-OX; ^D MCQ 4 weeks after each procedure, PCQ 4 weeks after each second procedure; ^E only during the first three procedures in the study.					

1 ePIPAC-OX

2 The procedure-related principles of (e)PIPAC have been extensively described by Willaert *et al* and
3 Giger-Pabst *et al*.^[24,48] In this study, ePIPAC-OX is performed at six-weekly intervals by at least one
4 PIPAC-qualified surgeon in a standard operating room with laminar airflow. In both study centres, the
5 operating personnel attended procedures in experienced PIPAC centres before performing their first
6 procedure. All procedures are performed under general anaesthesia. Antibiotic prophylaxis and
7 venous thromboembolism prophylaxis are not regularly administered. Before each procedure, a
8 checklist is used to ensure all materials are available. The operating personnel wears appropriate
9 chemotherapy-protective clothes according to existing HIPEC protocols.

10 The Hasson technique is used to insert a 10 mm blunt tip balloon trocar through the abdominal
11 wall. After obtaining a normothermic 12 mmHg capnoperitoneum, a second 10 mm blunt tip balloon
12 trocar is inserted under direct vision and explorative laparoscopy is performed. Only if needed, careful
13 adhesiolysis may be performed to create sufficient working space. In case of an iatrogenic bowel lesion,
14 the procedure is ended after closure of the lesion, and ePIPAC-OX may be postponed by two to four
15 weeks. If the procedure is considered feasible, leucovorin (20 mg/m² BSA in 10 minutes) and bolus 5-
16 fluorouracil (400 mg/m² BSA in 15 minutes) are administered intravenously. In the meantime, ascites
17 (or injected saline if ascites is not present) is completely evacuated, sent for cytology and translational
18 research, and the ascites volume is documented. Adhesions are scored with the Zühlke score, the
19 peritoneal cancer index (PCI) is registered, and photographs are taken throughout the peritoneal
20 cavity.^[49,50] A piece of normal peritoneum and three peritoneal metastases, preferably from
21 different areas, are biopsied, sent for histopathology and translational research, and their locations
22 are documented and marked with clips to enable biopsies of the same locations during subsequent
23 procedures.

24 Then, the ePIPAC setup is installed. A stainless steel brush electrode (Ionwand[®], Alesi Surgical,
25 Cardiff, United Kingdom) is inserted through a mini-trocar under direct vision, secured with its tip at
26 least 2 cm away from other structures, and connected to its generator (Ultravision[®], Alesi Surgical,
27 Cardiff, United Kingdom). A nebuliser (CapnoPen[®], Capnomed GmbH, Villingendorf, Germany) is
28 inserted through one of the trocars and secured with its nozzle just inside the peritoneal cavity at a
29 safe distance from visceral organs. The camera, inserted through the other trocar, is secured by a
30 laparoscope holder in a way it permanently visualises the electrode and the nebuliser. The valve of the
31 trocar connected to the CO₂ insufflation remains opened, whereas the other trocar is connected to a
32 closed aerosol waste system (CAWS) with its valve closed. The CAWS consecutively consists of a smoke
33 evacuation filter, a water seal drainage system, an infant-paediatric electrostatic microparticle filter,
34 and the air waste system of the hospital. The preoperatively prepared syringe with oxaliplatin (92
35 mg/m² BSA diluted in a total volume of 150 ml 5% dextrose) is vented, placed in a standard

1 angiographic injector, and connected to the nebuliser with a saline-flushed high-pressure line
2 protected by a plastic camera cover. A leak-free capnoperitoneum is ensured by zero-flow of CO₂. If
3 necessary, the external fascia may be additionally sutured and Luer lock caps may be placed on balloon
4 valves of trocars. The angiographic injector is installed at a flow rate of 30 ml/min and a maximum
5 pressure of 200 pounds per square inch. Protective films are placed on the floor below the
6 angiographic injector and around the patient. The angiographic injector is positioned above a
7 chemotherapy waste bin. The peripheral venous line of the patient is connected to a 60 ml saline-
8 containing syringe outside the operating room. Vital parameters of the patient, real-time
9 videolaparoscopy, and a patient-aimed camera are displayed on three screens outside the operating
10 room. The screen of the angiographic injector is positioned in front of the window of the operating
11 room. General anaesthesia is ensured for at least another 40 minutes. A checklist is used to confirm
12 that all aforementioned steps have been adequately taken. After completion of the checklist, the
13 entire operating personnel leaves the operating room.

14 Oxaliplatin is injected through the nebuliser by remote controlled activation of the
15 angiographic injector from outside the operating room. After complete formation of the oxaliplatin-
16 containing aerosol in 5 minutes, the surgeon enters the operating room and turns on the Ultravision®
17 generator, which results in electrostatic precipitation of the aerosol. The electrostatic field and the
18 capnoperitoneum are maintained for another 25 minutes. During this phase, the patient and the
19 procedure are monitored through the three screens and the window of the operating room. Drugs
20 may be administered to the patient through the intravenous access outside the operating room if
21 necessary.

22 After 25 minutes, the surgeon enters the operating room, turns off the Ultravision®
23 generator, closes the trocar valve connected to the CO₂ insufflation, and opens the trocar valve
24 connected to the CAWS. After complete evacuation of the aerosol, the electrode and the nebuliser are
25 removed, the entire operating personnel enters the operating room, and a new capnoperitoneum is
26 obtained. Ascites and peritoneal biopsies are collected for pharmacokinetic purposes. In case no
27 bleeding or perforations are observed, instruments are removed and incisions are closed with
28 absorbable sutures. All instruments and materials are directly disposed in chemotherapy waste bins
29 and the operating room is cleaned according to existing HIPEC protocols. Any procedure-related
30 mistake or difficulty during ePIPAC-OX is recorded directly after occurrence.

31 After ePIPAC-OX, patients are admitted to the general surgical ward. To relieve postoperative
32 pain, patients receive paracetamol (1 g, four times daily), on-demand morphine, and 1 g of metamizole
33 directly after the procedure. To minimise postoperative nausea and vomiting, patients receive
34 perioperative dexamethasone and on-demand granisetron (1 mg, three times daily). Standard post-
35 surgical clinical evaluations are performed a few hours after the procedure and on every postoperative

1 day. Blood is drawn for bone marrow, liver, and kidney functions, albumin, and C-reactive protein on every postoperative day. If the postoperative period is uneventful, patients are discharged on the first postoperative day. All body excretes are considered oxaliplatin-contaminated for up to five days after the procedure.

Dose reduction, prohibited and permitted concomitant care, and strategies to improve adherence are not specified *a priori*, but left to the discretion of the treating physician. ePIPAC-OX is repeated until clinical progression, radiological progression (Response Evaluation Criteria In Solid Tumours or at physician's discretion in case of non-measurable disease), macroscopic progression (i.e. ascites volume, PCI), unacceptable toxicity, physician's decision to discontinue, or at patient's request to discontinue. In patients who develop systemic metastases, continuation of ePIPAC-OX can only be considered if the patient has no systemic palliative treatment options and stable peritoneal disease.

Outpatient evaluations

One week after each ePIPAC-OX, patients undergo clinical evaluation by phone. Four weeks after each ePIPAC-OX, patients undergo radiological evaluation (i.e. thoracoabdominal CT, diffusion-weighted magnetic resonance imaging [DW-MRI]), biochemical evaluation (i.e. bone marrow, liver, and kidney functions, albumin, C-reactive protein, tumour markers), and clinical evaluation.

Questionnaires

Patients are asked to complete EQ-5D-5L, QLQ-C30, and QLQ-CR29 at baseline and one and four weeks after each ePIPAC-OX.[51-53] iMTA Productivity Cost Questionnaire (PCQ) and iMTA Medical Consumption Questionnaire (MCQ) are sent to the patients at baseline and four weeks after each ePIPAC-OX (PCQ) and each second ePIPAC-OX (MCQ).[54,55]

Pharmacokinetics

Blood is collected during and after the first three procedures in each patient. Four ml of whole blood is drawn and collected in heparin tubes before ePIPAC-OX and at 5, 10, 20, 30, 60, 120, 240, 360, and 1080 minutes after injection of oxaliplatin. After immediate centrifuging, an aliquot of plasma is stored at -80°C until analysis. Another aliquot of 1 ml of plasma is centrifuged through an ultrafiltration membrane and stored at -80°C until analysis. Urine, ascites, peritoneal metastases, and normal peritoneum are collected during and after all procedures. Four ml of urine is collected in urinalysis tubes before ePIPAC-OX and on the first postoperative day. These are stored at -20°C until analysis. After discharge, patients are asked to collect four ml of urine in urinalysis tubes on the third, fifth, and seventh postoperative day, and to store these specimens at their home address at -20°C until analysis. After electrostatic precipitation of the aerosol, the surgeon aspirates a few ml of ascites and biopsies

1 two peritoneal metastases and two pieces of normal peritoneum, preferably from different locations.
2 These are collected in aliquots and directly stored at -80°C until analysis. Concentrations of oxaliplatin
3 are measured by using atomic absorption spectrophotometry.
4

5 Translational research

6 Before each ePIPAC-OX, 20 ml of blood is drawn and collected in 10 ml Cell-free DNA BCT tubes (Streck,
7 La Vista, NE, USA). According to the manufacturer's instructions, these tubes are sent to a central lab
8 for isolation and storage (-80°C) of plasma and cell pellet. Collected ascites or saline is centrifuged
9 twice (5 minutes, 420 g, zero break) under sterile conditions. The supernatant is snap frozen and stored
10 at -80°C for further analysis on soluble components. The cell pellet is suspended in organoid culture
11 medium at 4°C for transport and further work up. Of each collected PM, three parts are snap frozen
12 and stored at -80°C for sequencing analysis.
13

14 Outcomes

15 An assessment schedule is presented in *Table 1*. The primary outcome is the number of patients with
16 major toxicity, defined as grade ≥ 3 according to the Common Terminology Criteria for Adverse Events
17 (CTCAE) v4.0,[56] up to four weeks after the last ePIPAC-OX. Secondary outcomes are:

- 18
- 19 ▪ the environmental safety of ePIPAC-OX, based on air and surface concentrations of oxaliplatin
20 during the first three procedures, measured by atomic absorption spectrophotometry;
- 21 ▪ procedure-related characteristics of ePIPAC-OX (e.g. intraoperative complications, amount of
22 adhesions, procedure-related mistakes and difficulties, operating time);
- 23 ▪ the number of procedures in each patient and reasons for discontinuation;
- 24 ▪ minor toxicity, defined as grade ≤ 2 according to CTCAE v4.0,[56] up to four weeks after the last
25 ePIPAC-OX;
- 26 ▪ major and minor postoperative complications, defined as grade ≥ 3 and grade ≤ 2 according to
27 Clavien-Dindo,[57] respectively, up to four weeks after the last ePIPAC-OX;
- 28 ▪ hospital stay, defined as the number of days between ePIPAC-OX and initial discharge;
- 29 ▪ readmissions, defined as any hospital admission after initial discharge, up to four weeks after
30 the last ePIPAC-OX;
- 31 ▪ radiological tumour response, based on central review of thoracoabdominal CT and DW-MRI
32 at baseline and four weeks after each ePIPAC-OX, performed by two independent radiologists
33 (JN, MLH) blinded to clinical outcomes (classification is not defined *a priori*);

- 1
- 2
- 3 1 ▪ histopathological tumour response, based on central review of collected peritoneal biopsies
- 4 2 during each ePIPAC-OX, performed by two independent pathologists (e.g. CJRH) blinded to
- 5 3 clinical outcomes by using the Peritoneal Regression Grading Score;[58]
- 6 4 ▪ macroscopic tumour response, based on PCI and ascites volume during each ePIPAC-OX;
- 7 5 ▪ biochemical tumour response, based on tumour markers measured at different time points
- 8 6 (Table 1);
- 9 7 ▪ cytological tumour response, based on collected ascites or peritoneal washing cytology during
- 10 8 each ePIPAC-OX;
- 11 9 ▪ quality of life, extracted from questionnaires (EQ-5D-5L, QLQ-C30, QLQ-CR29) at different time
- 12 10 points (Table 1);
- 13 11 ▪ costs, derived from the Dutch costing guidelines for health care research at the time of
- 14 12 analysis, based on case report forms, hospital information systems, and questionnaires (iMTA
- 15 13 PCQ, iMTA MCQ) at different time points (Table 1);
- 16 14 ▪ progression-free survival, defined as the time between enrolment and clinical, radiological, or
- 17 15 macroscopic progression, or death;
- 18 16 ▪ overall survival, defined as the time between enrolment and death;
- 19 17 ▪ the pharmacokinetics of oxaliplatin during and after ePIPAC-OX.
- 20 18
- 21 19
- 22 20
- 23 21
- 24 22
- 25 23
- 26 24
- 27 25
- 28 26
- 29 27
- 30 28
- 31 29
- 32 30
- 33 31
- 34 32
- 35 33
- 36 34
- 37 35
- 38 36
- 39 37
- 40 38
- 41 39
- 42 40
- 43 41
- 44 42
- 45 43
- 46 44
- 47 45
- 48 46
- 49 47
- 50 48
- 51 49
- 52 50
- 53 51
- 54 52
- 55 53
- 56 54
- 57 55
- 58 56
- 59 57
- 60 58

19 **Sample size**

20 Given the absence of evident clinical endpoint in this patient category, the investigators pragmatically
 21 determined the sample size of this exploratory study. The investigators agreed that 60 procedures are
 22 required to explore the feasibility, safety, tolerability, and preliminary efficacy of repetitive ePIPAC-OX
 23 in this setting. Since the expected mean number of procedures is three per patient,[36] the initial
 24 sample size is determined at 20 patients. This pragmatically determined sample size is approved by
 25 the central ethics committee. Enrolled patients who do not undergo a first ePIPAC-OX (e.g. systemic
 26 metastases on baseline radiology, non-access, resectable disease) are replaced to enrol 20 patients
 27 who receive at least one ePIPAC-OX.

29 **Recruitment**

30 The study started in October 2017 and is currently enrolling patients. The investigators anticipate that
 31 20 patients will be enrolled within a maximum of three years. Strategies for achieving adequate
 32 participant enrolment are not defined *a priori*.

34 **Data collection and data management**

1 Outcomes are collected in all patients who receive at least one ePIPAC-OX. All baseline characteristics
2 and clinical outcomes are prospectively collected and entered in an ISO 27001 certified central study
3 database (De Research Manager, Deventer, Netherlands) with study-specific electronic case report
4 forms by a local investigator in each study centre (RJL, ECEW). This ISO 27001 certified system ensures
5 adequate data integrity, including data coding, security, and storage. Questionnaires (quality of life,
6 costs), peritoneal biopsies (histopathological response), and radiological examinations (radiological
7 response) are collected by the coordinating investigator (KPR) throughout the study and centrally
8 analysed after study completion. Plans to promote data quality, participant retention, and complete
9 follow-up are not specified *a priori*.

11 **Statistical methods**

12 Repetitive continuous outcomes (e.g. quality of life, operating time) are analysed by using the
13 Wilcoxon signed-rank test, the paired samples t-test, the Friedman test, or repeated measurements
14 analysis of variance where appropriate. Repetitive categorical outcomes (e.g. intraoperative
15 complications, postoperative complications) are analysed by using the McNemar test, the Wilcoxon
16 signed-rank test, the Cochran's Q test, or generalised estimating equations where appropriate. Time-
17 to-event variables (i.e. overall and progression-free survival) are analysed and displayed by using the
18 Kaplan-Meier method. Other outcomes are analysed by using descriptive statistics. All statistical tests
19 are two-sided and $p < 0.05$ is considered statistically significant.

21 **Data monitoring**

22 Interim analyses are performed after 8 and 20 procedures. The study is terminated after these interim
23 analyses if CTCAE grade ≥ 3 toxicity, directly related to ePIPAC-OX, is observed after ≥ 4 and ≥ 10
24 procedures. Furthermore, the study is directly terminated if more than one CTCAE grade 5 toxicity,
25 directly related to ePIPAC-OX, occurs during the study. The coordinating investigator and the principal
26 investigator (IHJTH) have access to these interim results. The principal investigator makes the decision
27 to terminate or continue the study. The investigators decided that a data monitoring committee is not
28 needed given the clear stopping rules and the low expected toxicity of repetitive ePIPAC-OX.

30 **Harms**

31 Local investigators report all serious adverse events (SAEs) or suspected unexpected serious adverse
32 reactions (SUSARs) to the coordinating investigator within 24 hours. The coordinating investigator
33 reports SAEs/SUSARs to the ethics committee within seven days of first knowledge for lethal or life
34 threatening SAEs/SUSARs, and within fifteen days for other SAEs/SUSARs. The time window for
35 reporting SAEs/SUSARs is from enrolment up to four weeks after the last ePIPAC-OX.

1
2
3 1
4
5 2 **Auditing**
6
7 3 The study is audited by independent qualified monitors of Clinical Trial Centre Maastricht (Maastricht,
8
9 4 Netherlands) as a high-risk study according to the brochure 'Kwaliteitsborging mensgebonden
10
11 5 onderzoek 2.0' by the Dutch Federation of University Medical Centres. This means that study centres
12
13 6 are audited at least three times per year, depending on enrolment, with 100% auditing of the study
14
15 7 master file, investigator site files, informed consent forms, eligibility criteria, source data verification,
16
17 8 and SAEs/SUSARs.
18
19 9

10 **Patient and public involvement**

11 Patients were not involved in the study design before the start of the study. Shortly after the start of
12
13 12 the study, the investigators presented the study design to a patient advisory group. Major topics of
14
15 13 discussion were the rationale for the study, outcome parameters, recruitment strategies, the patient
16
17 14 information sheet, dissemination strategies, and the potential risks, benefits, and burden of
18
19 15 participation from the patient's perspective. The patient advisory group supported the presented
20
21 16 study design. Although the patient advisory group is not involved in the recruitment and the conduct
22
23 17 of the study, they will be involved in plans to disseminate the study results to relevant patient groups.
24
25 18

19 **ETHICS AND DISSEMINATION**

20 **Research ethics approval**

21 This study is approved by an ethics committee (MEC-U, Nieuwegein, Netherlands, R17.038), the Dutch
22
23 22 competent authority (Centrale Commissie Mensgebonden Onderzoek, NL60405.100.17), and the
24
25 23 institutional review boards of Catharina Hospital (Lokale Uitvoerbaarheidscommissie, CZE-2017.50)
26
27 24 and St. Antonius Hospital (R&D, L18.021).
28
29 25

26 **Protocol amendments**

27 Important protocol modifications are communicated to the ethics committee, the Dutch competent
28
29 28 authority, the institutional review boards of both study centres, all investigators, and trial registries.
30
31 29

30 **Consent or assent**

31 Written informed consent is obtained by local investigators at the outpatient clinic of the study
32
33 32 centres. Patients are given the possibility to give separate permission for undergoing DW-MRI and for
34
35 33 storage of specimens for translational research.
36
37 34

35 **Confidentiality**

1
2
3 1 Personal information about potential and enrolled patients is collected, shared, and maintained
4
5 2 according to the Dutch law (Wet Bescherming Persoonsgegevens).
6
7 3

8 4 **Declaration of interests**

9
10 5 The investigators declare no competing interests. The funders have no role in the study design, in
11
12 6 writing the report, or in the decision to submit the report for publication.
13
14 7

15 8 **Access to data**

16
17 9 All investigators have access to the final datasets, without contractual agreements that limit such
18
19 10 access.
20
21 11

22 12 **Ancillary and post-study care**

23
24 13 The sponsor (Catharina Hospital, Eindhoven, Netherlands) is insured to provide cover for patients who
25
26 14 suffer harm from study participation. After discontinuation of ePIPAC-OX, patients receive standard
27
28 15 palliative treatment for unresectable metastatic colorectal cancer according to Dutch guidelines.[4]
29
30 16

31 17 **Dissemination policy**

32
33 18 Results of the study are personally communicated to participants and intended for publication in peer-
34
35 19 reviewed medical journals and for presentation to patients, healthcare professionals, and other
36
37 20 stakeholders. Authorship eligibility guidelines for the main manuscript and manuscript of side studies
38
39 21 are not defined *a priori*. The full protocol and Dutch informed consent forms are, or will become,
40
41 22 available upon reasonable request.
42
43 23

44 24 **DISCUSSION**

45
46 25 To the knowledge of the investigators, this is the first study that prospectively explores the feasibility,
47
48 26 safety, tolerability, costs, preliminary efficacy, and pharmacokinetics of repetitive ePIPAC-OX as a
49
50 27 palliative monotherapy in patients with isolated unresectable colorectal PM.

51
52 28 This study protocol has potential limitations. The broad eligibility criteria could lead to a
53
54 29 heterogeneous cohort with various primary tumours (i.e. colon, appendix) and histologies (e.g. signet
55
56 30 ring cell carcinoma, high-grade appendiceal mucinous neoplasm) in different lines of treatment. This
57
58 31 clinical heterogeneity could impede the interpretation of survival outcomes. However, survival
59
60 32 outcomes are not the major focus of this study. Enrolment is also allowed for patients with an
33
34 33 unresected primary tumour and patients who did not receive prior palliative systemic therapy. In these
35
36 34 patients, administration of repetitive ePIPAC-OX as a monotherapy could theoretically lead to
37
38 35 undertreatment and subsequent systemic progression or progression of the primary tumour.

1
2
3 1 However, it is thought that the frequent clinical and radiological evaluations detect such progression
4 2 in a sufficiently early stage. Moreover, patients need to be informed by a medical oncologist about the
5 3 potential consequences of postponing or discontinuing their standard palliative treatment prior to
6 4 enrolment. Conclusively, the investigators feel that these controlled circumstances justify enrolment
7 5 of these patients.
8
9

10 6 This study protocol has potential strengths. All endpoints are predefined and prospectively
11 7 assessed. Independent 100% auditing ensures an appropriately conducted study and high-quality data.
12 8 Unlike other studies, repetitive ePIPAC-OX is administered as a palliative monotherapy in all patients.
13 9 Thereby, outcomes are not influenced by concurrent palliative systemic therapy. Extensive assessment
14 10 of quality of life provides insights in the tolerability of ePIPAC-OX from a patient perspective, whereas
15 11 pharmacokinetic analyses provide the first insights in the systemic absorption repetitive ePIPAC-OX.
16 12 Insights in the costs of ePIPAC-OX could be valuable for policy makers and other teams that aim to
17 13 implement this procedure or apply for scientific grants, while translational side studies may open new
18 14 avenues for research.
19
20
21
22
23
24
25
26
27

28 16 REFERENCES

- 29
30 17 [1] van Gestel YR, de Hingh IH, van Herk-Sukel MP, et al. Patterns of metachronous metastases after
31 18 curative treatment of colorectal cancer. *Cancer Epidemiol* 2014;38:448-54.
32
33 19 [2] van der Geest LG, Lam-Boer J, Koopman M, et al. Nationwide trends in incidence, treatment and
34 20 survival of colorectal cancer patients with synchronous metastases. *Clin Exp Metastasis* 2015;32:457-
35 21 65.
36
37 22 [3] Razenberg LG, Lemmens VE, Verwaal VJ, et al. Challenging the dogma of colorectal peritoneal
38 23 metastases as an untreatable condition: results of a population-based study. *Eur J Cancer* 2016;65:113-
39 24 20.
40
41 25 [4] Landelijke werkgroep Gastro Intestinale Tumoren. Richtlijn colorectaal carcinoom. 2014.
42 26 <https://www.oncoline.nl/colorectaalcarcinoom>. Accessed 10 Dec 2018.
43
44 27 [5] Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer
45 28 given systemic therapy: an analysis of individual patient data from prospective randomised trials from
46 29 the Analysis and Research in Cancers of the Digestive System (ARCAD) database. *Lancet Oncol*
47 30 2016;17:1709-19.
48
49 31 [6] Sugarbaker PH, Stuart OA, Vidal-Jove J, et al. Pharmacokinetics of the peritoneal-plasma barrier
50 32 after systemic mitomycin C administration. *Cancer Treat Res* 1996;82:41-52.
51
52 33 [7] Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug
53 34 administration in the treatment of ovarian cancer. *Cancer Treat Rep* 1978;62:1-11.
54
55 35 [8] Jacquet P, Sugarbaker PH. Peritoneal-plasma-barrier. *Cancer Treat Res* 1996;82:53-63.
56
57
58
59
60

- 1
2
3 1 [9] Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue
4 2 penetration and surface exposure. *J Natl Cancer Inst* 1997;89:480-7.
- 5 3 [10] Markman M. Limited use of the intraperitoneal route for ovarian cancer – why? *Nat Rev Clin Oncol*
6 4 2015;12:628-30.
- 7 5 [11] Solass W, Hetzel A, Schwarz T, et al. PIPAC Technology. In: Reymond MA, Solass W. Pressurized
8 6 IntraPeritoneal Aerosol Chemotherapy – Cancer under Pressure. De Gruyter, 2014.
- 9 7 [12] Reymond MA, Hu B, Garcia A, et al. Feasibility of therapeutic pneumoperitoneum in a large animal
10 8 model using a microvaporisator. *Surg Endosc* 2000;14:51-5.
- 11 9 [13] Jacquet P, Stuart OA, Chang D, et al. Effects of intra-abdominal pressure on pharmacokinetics and
12 10 tissue distribution of doxorubicin after intraperitoneal administration. *Anticancer Drugs* 1996;7:596-
13 11 603.
- 14 12 [14] Esquis P, Consolo D, Magnin G, et al. High intra-abdominal pressure enhances the penetration and
15 13 antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. *Ann Surg*
16 14 2006;244:106-12.
- 17 15 [15] Solass W, Herbette A, Schwarz T, et al. Therapeutic approach of human peritoneal carcinomatosis
18 16 with Dbait in combination with capnoperitoneum: proof of concept. *Surg Endosc* 2012;26:847-52.
- 19 17 [16] Solass W, Hetzel A, Nadiradze G, et al. Description of a novel approach for intraperitoneal drug
20 18 delivery and the related device. *Surg Endosc* 2012;26:1849-55.
- 21 19 [17] Facy O, Al Samman S, Magnin G, et al. High pressure enhances the effect of hyperthermia in
22 20 intraperitoneal chemotherapy with oxaliplatin: an experimental study. *Ann Surg* 2012;256:1084-8.
- 23 21 [18] Solass W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis
24 22 using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. *Ann Surg Oncol*
25 23 2014;21:553-9.
- 26 24 [19] Blanco A, Giger-Pabst U, Solass W, et al. Renal and hepatic toxicities after pressurized
27 25 intraperitoneal aerosol chemotherapy (PIPAC). *Ann Surg Oncol* 2013;20:2311-6.
- 28 26 [20] Eveno C, Haidara A, Ali I, et al. Experimental pharmacokinetics evaluation of chemotherapy
29 27 delivery by PIPAC for colon cancer: first evidence for efficacy. *Pleura and Peritoneum* 2017;2:103-109.
- 30 28 [21] Grass F, Vuagnieaux A, Teixeira-Farinha H, et al. Systematic review of pressurized intraperitoneal
31 29 aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. *Br J Surg*
32 30 2017;104:669-78.
- 33 31 [22] Tempfer C, Giger-Pabst U, Hilal Z, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
34 32 for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special
35 33 emphasis on ovarian cancer. *Arch Gynecol Obstet* 2018;298:243-57.
- 36 34 [23] Nowacki M, Alyami M, Villeneuve L, et al. Multicenter comprehensive methodological and
37 35 technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions

- 1 performed in 349 patients for peritoneal carcinomatosis treatment: an international survey study. *Eur*
2 *J Surg Oncol* 2018;44:991-6.
- 3 [24] Willaert W, Sessink P, Ceelen W. Occupational safety of pressurized intraperitoneal aerosol
4 chemotherapy (PIPAC). *Pleura and Peritoneum* 2017;2:121-8.
- 5 [25] Graversen M, Lundell L, Fristrup C, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
6 as an outpatient procedure. *Pleura and Peritoneum* 2018;20180128.
- 7 [26] Kakchekeeva T, Demtröder C, Herath NI, et al. In vivo feasibility of electrostatic precipitation as an
8 adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC). *Ann Surg Oncol* 2016;23(Suppl
9 5):592-8.
- 10 [27] Odendahl K, Solass W, Demtröder C, et al. Quality of life of patients with end-stage peritoneal
11 metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). *Eur J Surg Oncol*
12 2015;41:1379-85.
- 13 [28] Robella M, Vaira M, de Simone M. Safety and feasibility of pressurized intraperitoneal aerosol
14 chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat
15 peritoneal carcinomatosis. *World J Surg Oncol* 2016;14:128.
- 16 [29] Teixeira Farinha H, Grass F, Kefleyesus A, et al. Impact of pressurized intraperitoneal aerosol
17 chemotherapy on quality of life and symptoms in patients with peritoneal carcinomatosis: a
18 retrospective cohort study. *Gastroenterol Res Pract* 2017;2017:4596176.
- 19 [30] Hübner M, Teixeira Farinha H, Grass F, et al. Feasibility and safety of pressurized intraperitoneal
20 aerosol chemotherapy for peritoneal carcinomatosis: a retrospective cohort study. *Gastroenterol Res*
21 *Pract* 2017;2017:6852749.
- 22 [31] Hübner M, Grass F, Teixeira-Farinha H, et al. Pressurized intraperitoneal aerosol chemotherapy –
23 practical aspects. *Eur J Surg Oncol* 2017;43:1102-9.
- 24 [32] Alyami M, Gagniere J, Sgarbura O, et al. Multicentric initial experience with the use of the
25 pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable
26 peritoneal carcinomatosis. *Eur J Surg Oncol* 2017;43:2178-83.
- 27 [33] Graversen M, Detlefsen S, Bjerregaard JK, et al. Prospective, single-center implementation and
28 response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal
29 metastasis. *Ther Adv Med Oncol* 2018;10:1758835918777036.
- 30 [34] Kurtz F, Struller F, Horvath P, et al. Feasibility, safety, and efficacy of pressurized intraperitoneal
31 aerosol chemotherapy (PIPAC) for peritoneal metastasis: a registry study. *Gastroenterol Res Pract*
32 2018;2018:2743985.
- 33 [35] Teixeira Farinha H, Grass F, Labгаа I, et al. Inflammatory response and toxicity after pressurized
34 intraperitoneal aerosol chemotherapy. *J Cancer* 2018;9:13-20.

- 1
2
3 1 [36] Demtröder C, Solass W, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy with
4 2 oxaliplatin in colorectal peritoneal metastasis. *Colorectal Dis* 2016;18:364-71.
- 5 3 [37] Graversen M, Detlefsen S, Pfeiffer P, et al. Severe peritoneal sclerosis after repeated pressurized
6 4 intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature
7 5 survey. *Clin Exp Metastasis* 2018;35:103-8.
- 8 6 [38] Siebert M, Alyami M, Mercier F, et al. Severe hypersensitivity reactions to platinum compounds
9 7 post-pressurized intraperitoneal aerosol chemotherapy (PIPAC): first literature report. *Cancer
10 8 Chemother Pharmacol* Published Online First: 3 Dec 2018. doi: 10.1007/s00280-018-3740-3.
- 11 9 [39] Clinicaltrials.gov. www.clinicaltrials.gov. Accessed 10 Dec 2018.
- 12 10 [40] Solass W, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC):
13 11 occupational health and safety aspects. *Ann Surg Oncol* 2013;20:3504-11.
- 14 12 [41] Graversen M, Pedersen PB, Mortensen MB. Environmental safety during the administration of
15 13 Pressurized intraperitoneal aerosol chemotherapy (PIPAC). *Pleura and Peritoneum* 2016;1:203-8.
- 16 14 [42] Ndaw S, Hanser O, Kenepekian V, et al. Occupational exposure to platinum drugs during
17 15 intraperitoneal chemotherapy. Biomonitoring and surface contamination. *Toxicol Lett* 2018;298:171-
18 16 6.
- 19 17 [43] Ametsbichler P, Böhlandt A, Nowak D, et al. Occupational exposure to cisplatin/oxaliplatin during
20 18 pressurized intraperitoneal aerosol chemotherapy (PIPAC)? *Eur J Surg Oncol* 2018;44:1793-9.
- 21 19 [44] Dumont F, Senellart H, Pein F, et al. Phase I/II study of oxaliplatin dose escalation via a laparoscopic
22 20 approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable
23 21 peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): rationale and design.
24 22 *Pleura and Peritoneum* 2018;20180120
- 25 23 [45] Kim G, Tan HL, Chen E, et al. Study protocol: phase 1 dose escalating study of pressurized
26 24 intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis. *Pleura and
27 25 Peritoneum* 2018;20180118.
- 28 26 [46] Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after
29 27 complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. *Ann Oncol*
30 28 2002;13:267-72.
- 31 29 [47] Giachetti S, Perpoint B, Zidani R, et al. Phase III multicentre randomized trial of oxaliplatin added
32 30 to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. *J
33 31 Clin Oncol* 2000;18:136-47.
- 34 32 [48] Giger-Pabst U, Tempfer CB. How to perform safe and technically optimized pressurized
35 33 intraperitoneal aerosol chemotherapy (PIPAC): experience after a consecutive series of 1200
36 34 procedures. *J Gastrointest Surg* 2018;22:2187-93.

- 1
2
3 1 [49] Zühlke HV, Lorenz EM, Straub EM, et al. Pathophysiology and classification of adhesions.
4 2 *Langenbecks Arch Chir II Verh Dtsch Ges Chir* 1990;1009-16.
- 5 3 [50] Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients
6 4 with peritoneal carcinomatosis. *Cancer Treat Res* 1996;82:359-74.
- 7 5 [51] Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level
8 6 version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;20:1727-36.
- 9 7 [52] Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and
10 8 Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in
11 9 oncology. *J Natl Cancer Inst* 1993;85:365-76.
- 12 10 [53] Stiggelbout AM, Kunneman M, Baas-Thijssen MC, et al. The EORTC QLQ-CR29 quality of life
13 11 questionnaire for colorectal cancer: validation of the Dutch version. *Qual Life Res* 2016;25:1853-8.
- 14 12 [54] Bouwmans C, Krol M, Severens H, et al. The iMTA Productivity Cost Questionnaire: a standardized
15 13 instrument for measuring and valuing health-related productivity losses. *Value Health* 2015;18:753-8.
- 16 14 [55] iMTA: questionnaires. <https://www.imta.nl/questionnaires/>. Accessed 10 Dec 2018.
- 17 15 [56] Common Terminology Criteria for Adverse Events (CTCAE) v4.0. National Cancer Institute. 2009.
18 16 [https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-](https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf)
19 17 [29_QuickReference_8.5x11.pdf](https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf). Accessed 10 Dec 2018.
- 20 18 [57] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with
21 19 evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;240:205-13.
- 22 20 [58] Solass W, Sempoux C, Carr N, et al. Reproducibility of the Peritoneal Regression Grading Score
23 21 (PRGS) for assessment of response to therapy in peritoneal metastasis. *Histopathology* Published
24 22 Online First: 27 Jan 2019. doi:10.1111/his.13829.

23 24 **ACKNOWLEDGEMENTS**

25 None.

26 27 **AUTHORS' CONTRIBUTIONS**

28 KPR is the coordinating investigator. RJL, AMJT, GMC, JWAB, SWN are the local investigators of the first
29 study centre. ECEW, and TJMK, ML, MJW, and DB are the local investigators of the second study centre.
30 RT performs the pharmacokinetic analyses. MJD is the study pharmacologist supervising the
31 pharmacokinetic analyses. JN and MJL are the study radiologists performing the central radiological
32 review. CJRH is the study pathologist performing the central histopathological review. HJS is the study
33 anaesthesiologist who developed the protocols for perioperative care. IE and RJAF are responsible for
34 translational research on blood. AC and OK are responsible for translational research on ascites and
35 PM. IHJTH is the principal investigator. KPR, RJL, and IHJTH made substantial contributions to

1
2
3 1 conception and design of the study, drafted the protocol, and drafted the manuscript. All other
4 authors made substantial contributions to conception and design of the study and critically revised the
5 protocol and the manuscript for important intellectual content. All authors gave final approval of the
6 version to be published and agree to be accountable for all aspects of the work.
7
8
9

10 **FUNDING**

11 This study is supported by Catharina Research Foundation (grant number: 2017-5) and St. Antonius
12 Research Foundation (grant number: 17.4).
13
14
15
16
17

18 **COMPETING INTERESTS**

19 None declared.
20
21
22

23 **ETHICAL APPROVAL**

24 This study is approved by an ethics committee (MEC-U, Nieuwegein, Netherlands, number R17.038),
25 the Dutch competent authority (CCMO, The Hague, Netherlands), and the institutional review boards
26 of both study centres.
27
28
29
30

31 **DATA SHARING**

32 Not applicable.
33
34
35

36 **PATIENT CONSENT**

37 Not applicable.
38
39
40

41 **PROTOCOL VERSION**

42 Version 6, 10 January 2019
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60








1
2


FIGURE TITLES

Figure 1. Flow chart of the CRC-PIPAC study

FIGURE LEGENDS

Figure 1. *ePIPAC-OX* electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin;

- | | |
|---|---|
|  | Bloods (organ functions, tumour markers) |
|  | Cytology (ascites or peritoneal washing with saline) |
|  | Histopathology (peritoneal biopsies) |
|  | Pharmacokinetics (blood, urine, ascites, PM, normal peritoneum) |
|  | Questionnaires (quality of life, costs) |
|  | Radiology (thoracoabdominal CT, diffusion-weighted MRI) |
|  | Translational research (blood, ascites, PM) |





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
	2b	All items from the World Health Organization Trial Registration Data Set	Entire manuscript
Protocol version	3	Date and version identifier	20
Funding	4	Sources and types of financial, material, and other support	20
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1-2, 19-20
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	14
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	Entire manuscript

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention **3-5**

4

5

6 6b Explanation for choice of comparators **Not applicable**

7

8 Objectives 7 Specific objectives or hypotheses **5**

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) **6**

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained **6**

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) **6**

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered **6-11**

23

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) **9**

26

27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) **9**

29

30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial **9**

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended **11-12**

35

36

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) **Table 1, Figure 1**

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	12
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	12
5				

6
7 **Methods: Assignment of interventions (for controlled trials)**

8
9 Allocation:

10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Not applicable
11				
12				
13				
14				
15				
16	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	Not applicable
17				
18				
19				
20				
21	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	Not applicable
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	Not applicable
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	Not applicable
28				
29				
30				

31 **Methods: Data collection, management, and analysis**

32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	12
34				
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	12
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	12
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	13
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	Not applicable
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	12
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	13
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	13
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	13
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	13
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	14
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	14
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	14
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	14
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	14
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	14
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	14
14				
15				
16				
17	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	15
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	15
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	15
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	15
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Available upon request
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	10
35				
36				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons [“Attribution-NonCommercial-NoDerivs 3.0 Unported”](https://creativecommons.org/licenses/by/4.0/) license.

BMJ Open

Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC).

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-030408.R2
Article Type:	Protocol
Date Submitted by the Author:	12-Jun-2019
Complete List of Authors:	Rovers, Koen; Catharina Hospital, Surgery Lurvink, Robin; Catharina Hospital, Surgery Wassenaar, Emma; Sint Antonius Hospital, Surgery Kootstra, Thomas; Sint Antonius Hospital, Surgery Scholten, Harm; Catharina Hospital, Anaesthesiology Tajzai, Rudaba; Catharina Hospital, Clinical Pharmacy Deenen, Maarten; Catharina Hospital, Clinical Pharmacy Nederend, Joost; Catharina Hospital, Radiology Lahaye, Max; Netherlands Cancer Institute, Radiology Huysentruyt, Clément; Catharina Hospital, Pathology van 't Erve, Iris; Netherlands Cancer Institute, Pathology Fijneman, Remond; Netherlands Cancer Institute, Pathology Constantinides, Alexander; UMC Utrecht, Imaging and Cancer Kranenburg, Onno; UMC Utrecht, Imaging and Cancer Los, Maartje; Sint Antonius Hospital, Medical Oncology Thijs, Annemarie; Catharina Hospital, Medical Oncology Creemers, Geert-Jan; Catharina Hospital, Medical Oncology Burger, Jacobus; Catharina Hospital, Surgery Wiezer, René; Sint Antonius Hospital, Surgery Boerma, Djamila ; Sint Antonius Hospital, Surgery Nienhuijs, Simon W.; Catharina Hospital, Surgery de Hingh, Ignace; Catharina Hospital, Surgery
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Gastroenterology and hepatology, Surgery
Keywords:	PIPAC, Peritoneal metastases, Colorectal cancer, Colorectal surgery < SURGERY, Gastrointestinal tumours < ONCOLOGY, Intraperitoneal chemotherapy

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Title

Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy (ePIPAC) with oxaliplatin as a palliative monotherapy for isolated unresectable colorectal peritoneal metastases: protocol of a Dutch, multicentre, open-label, single-arm, phase II study (CRC-PIPAC).

Corresponding author

Prof. dr. I.H.J.T. (Ignace) de Hingh, MD, PhD;
Department of Surgery, Catharina Hospital;
PO Box 1350, 5602 ZA, Eindhoven, Netherlands;
E-mail: ignace.d.hingh@catharinaziekenhuis.nl;
Telephone: +31402397150.

Authors

Koen P. Rovers¹; Robin J. Lurvink¹; Emma C.E. Wassenaar²; Thomas J.M. Kootstra²; Harm J. Scholten³; Rudaba Tajzai^{1,4}; Maarten J. Deenen^{4,5}; Joost Nederend⁶; Max J. Lahaye⁷; Clément J.R. Huysentruyt⁸; Iris van 't Erve⁹; Remond J.A. Fijneman⁹; Alexander Constantinides¹⁰; Onno Kranenburg¹⁰; Maartje Los¹¹; Anna M.J. Thijs¹²; Geert-Jan M. Creemers¹²; Jacobus W.A. Burger¹; Marinus (René) J. Wiezer²; Djamila Boerma²; Simon W. Nienhuijs¹; Ignace H.J.T. de Hingh^{1,13}.

Affiliations

¹Department of Surgery, Catharina Hospital, Eindhoven, Netherlands;

²Department of Surgery, St. Antonius Hospital, Nieuwegein, Netherlands;

³Department of Anaesthesiology, Catharina Hospital, Eindhoven, Netherlands;

⁴Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, Netherlands;

⁵Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, Netherlands;

⁶Department of Radiology, Catharina Hospital, Eindhoven, Netherlands;

⁷Department of Radiology, Netherlands Cancer Institute, Amsterdam, Netherlands;

⁸Department of Pathology, Catharina Hospital, Eindhoven, Netherlands;

⁹Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands;

¹⁰Imaging and Cancer, Utrecht Platform for Organoid Technology, University Medical Centre Utrecht, Utrecht, Netherlands;

¹¹Department of Medical Oncology, St. Antonius Hospital, Nieuwegein, Netherlands;

¹²Department of Medical Oncology, Catharina Hospital, Eindhoven, Netherlands;

1
2
3 1 ¹³Grow – School for Oncology and Developmental Biology, Maastricht University, Maastricht,
4
5 2 Netherlands

6
7 3
8 4 **Word count**

9 5 3988.
10
11 6

12
13 7 **Abstract**

14 8 *Introduction:* Repetitive electrostatic pressurised intraperitoneal aerosol chemotherapy with
15 9 oxaliplatin (ePIPAC-OX) is offered as a palliative treatment option for patients with isolated
16 10 unresectable colorectal peritoneal metastases (PM) in several centres worldwide. However, little is
17 11 known about its feasibility, safety, tolerability, efficacy, costs, and pharmacokinetics in this setting. This
18 12 study aims to explore these parameters in patients with isolated unresectable colorectal PM who
19 13 receive repetitive ePIPAC-OX as a palliative monotherapy.

20 14 *Methods and analysis:* This multicentre, open-label, single-arm, phase II study is performed in two
21 15 Dutch tertiary referral hospitals for the surgical treatment of colorectal PM. Eligible patients are adults
22 16 who have histologically or cytologically proven isolated unresectable PM of a colorectal or appendiceal
23 17 carcinoma, a good performance status, adequate organ functions, and no symptoms of
24 18 gastrointestinal obstruction. Instead of standard palliative treatment, enrolled patients receive
25 19 laparoscopy-controlled ePIPAC-OX (92 mg/m² body-surface area [BSA]) with intravenous leucovorin
26 20 (20 mg/m² BSA) and bolus 5-fluorouracil (400 mg/m² BSA) every six weeks. Four weeks after each
27 21 procedure, patients undergo clinical, radiological, and biochemical evaluation. ePIPAC-OX is repeated
28 22 until disease progression, after which standard palliative treatment is (re)considered. The primary
29 23 outcome is the number of patients with major toxicity (grade ≥ 3 according to the Common
30 24 Terminology Criteria for Adverse Events v4.0) up to four weeks after the last ePIPAC-OX. Secondary
31 25 outcomes are the environmental safety of ePIPAC-OX, procedure-related characteristics, minor
32 26 toxicity, postoperative complications, hospital stay, readmissions, quality of life, costs,
33 27 pharmacokinetics of oxaliplatin, progression-free survival, overall survival, and the radiological,
34 28 histopathological, cytological, biochemical, and macroscopic tumour response.

35 29 *Ethics and dissemination:* This study is approved by an ethics committee, the Dutch competent
36 30 authority, and the institutional review boards of both study centres. Results are intended for
37 31 publication in peer-reviewed medical journals and for presentation to patients, healthcare
38 32 professionals, and other stakeholders.

39 33 *Registration:* ClinicalTrials.gov/NCT03246321, ISRCTN/ISRCTN89947480, NTR/NTR6603,
40 34 EudraCT/2017-000927-29.
41 35

1
2
3 1 Currently, pressurised intraperitoneal aerosol chemotherapy (PIPAC) is one of these systems that
4 2 internationally gains the most attention.
5
6 3

4 **Pressurised intraperitoneal aerosol chemotherapy (PIPAC)**

5 PIPAC is a laparoscopy-controlled repetitive intraperitoneal administration of low-dose chemotherapy
6 as a pressurised aerosol.[11,12] It combines the theoretical pharmacokinetic advantages of low-dose
7 intraperitoneal chemotherapy (i.e. low toxicity, high intraperitoneal concentration, low systemic
8 concentration) with the principles of an aerosol (homogeneous intraperitoneal distribution) and intra-
9 abdominal pressure (deep tissue penetration).[13-20] Two groups systematically reviewed results of
10 non-comparative clinical studies that assessed the feasibility, safety, tolerability, and preliminary
11 efficacy of PIPAC with various drugs for PM of various origins.[21,22] They concluded that PIPAC is a
12 safe, feasible, and well tolerated treatment with good preliminary response rates.[21,22] These
13 preliminary conclusions have led to an increasing acceptance of PIPAC as a palliative treatment option
14 for PM in several centres worldwide.[23] In these centres, patients with isolated unresectable
15 colorectal PM usually receive PIPAC with oxaliplatin (PIPAC-OX) in an empirically chosen dosage of 92
16 mg/m² body-surface area (BSA) every four to six weeks.[23] Some centres use electrostatic
17 precipitation of the aerosol during PIPAC-OX (ePIPAC-OX),[24,25] since this could increase tissue
18 penetration of oxaliplatin.[26]

20 **PIPAC for colorectal PM**

21 Several clinical studies included patients who received repetitive PIPAC-OX for colorectal PM.[27-36]
22 However, the vast majority of these studies reported outcomes of entire cohorts that received
23 repetitive PIPAC with various drugs for PM of various origins without presenting subgroup analyses of
24 patients who received PIPAC-OX for colorectal PM.[27-34] Only two studies reported separate
25 outcomes of repetitive PIPAC-OX for colorectal PM.[35,36] By using a prospectively maintained
26 database, Teixeira-Farinha *et al* retrospectively included 20 patients with isolated colorectal PM who
27 received 37 procedures.[35] They concluded that repetitive PIPAC-OX causes a modest and transitory
28 inflammatory response without haematological, renal, or hepatic toxicity.[35] Demtröder *et al.*
29 retrospectively included 17 patients with isolated colorectal PM who received 48 procedures within
30 an off-label program.[36] They concluded that repetitive PIPAC-OX induces regression of pretreated
31 colorectal PM and that the toxicity seems to be low.[36] Both studies have a retrospective design
32 without predefined eligibility criteria and endpoints. Moreover, both studies included patients who
33 received repetitive PIPAC-OX as a monotherapy as well as patients who received PIPAC-OX in
34 combination with palliative systemic therapy. These shortcomings strongly impede the interpretation

1 of these studies. Besides, recently published case reports suggested that PIPAC-OX could lead to severe
2 hypersensitivity reactions and peritoneal sclerosis.[37,38]

3 4 **Rationale for this study**

5 In conclusion, little is known about the safety, tolerability, and efficacy of repetitive PIPAC-OX in
6 patients with isolated unresectable colorectal PM, whereas nothing is known about its costs and
7 pharmacokinetics. Specifically for repetitive ePIPAC-OX, all these outcomes have never been reported.
8 This questions the current use of repetitive ePIPAC-OX as a palliative treatment option for isolated
9 unresectable colorectal PM outside the framework of clinical study protocols. Ideally, these patients
10 are included in prospective studies with predefined eligibility criteria, interventions, and endpoints.
11 However, by the knowledge of the investigators, such studies are currently lacking and not
12 ongoing.[39] Therefore, this study aims to prospectively explore the safety, tolerability, preliminary
13 efficacy, costs, and pharmacokinetics of repetitive ePIPAC-OX as a palliative treatment for isolated
14 unresectable colorectal PM. Although implementation of PIPAC appears feasible and occupationally
15 safe,[21,22,24,40-43] there is no experience with PIPAC in the Netherlands. Hence, this study also aims
16 to assess the feasibility of implementation of ePIPAC-OX in two Dutch tertiary referral hospitals for the
17 surgical treatment of colorectal PM.

18 19 **Rationale for intervention**

20 Repetitive ePIPAC-OX may be administered as part of a bidirectional therapy with palliative systemic
21 therapy or as a monotherapy. The bidirectional therapy hypothetically maximises tumour response,
22 probably at the cost of an increased treatment burden that could interfere with quality of life.
23 Repetitive ePIPAC-OX as a monotherapy hypothetically temporarily stabilises the intraperitoneal
24 disease burden with minimal toxicity and preservation of quality of life. For this study, the investigators
25 decided to administer repetitive ePIPAC-OX as a palliative monotherapy with (re)consideration of
26 standard palliative treatment upon progression. According to internationally used protocols, ePIPAC-
27 OX is administered in a dosage of 92 mg/m² at six-weekly intervals.[23] The investigators actively
28 followed two ongoing phase I studies in which repetitive PIPAC-OX is administered in various pre-
29 planned dosage levels to evaluate whether the dosage of oxaliplatin in this study needs to be
30 modified.[44,45] Before administration of ePIPAC-OX, patients receive intravenous low-dose
31 leucovorin with bolus 5-fluorouracil, since this is thought to potentiate the effect of intraperitoneal
32 oxaliplatin.[46,47]

33 34 **METHODS AND ANALYSIS**

35 **Design and setting**

1
2
3 1 This prospective, open-label, single-arm, phase II study is performed in two Dutch teaching hospitals
4 2 qualified as tertiary referral hospitals for the surgical treatment of colorectal PM.
5
6
7 3

8 4 **Eligibility criteria**

9 5 Eligible patients are adults who have:

- 10 6
- 11 7 ▪ a World Health Organisation (WHO) performance status of ≤ 1 ;
 - 12 8 ▪ histological or cytological proof of PM of a colorectal or appendiceal carcinoma;
 - 13 9 ▪ unresectable disease determined by the treating physician, based on abdominal computed
14 10 tomography (CT) and a diagnostic laparotomy or laparoscopy, the latter being a standard tool
15 11 in the diagnostic work-up of patients with isolated colorectal PM in the Netherlands;
 - 16 12 ▪ adequate organ functions (haemoglobin ≥ 5.0 mmol/L, neutrophils $\geq 1.5 \times 10^9$ /L, platelets ≥ 100
17 13 $\times 10^9$ /L, serum creatinine $< 1.5 \times$ upper limit of normal [ULN], creatinine clearance ≥ 30 ml/min,
18 14 and liver transaminases $< 5 \times$ ULN);
 - 19 15 ▪ no symptoms of gastrointestinal obstruction;
 - 20 16 ▪ no radiological evidence of systemic metastases;
 - 21 17 ▪ no contraindications for oxaliplatin or 5-fluorouracil/leucovorin;
 - 22 18 ▪ no contraindications for a laparoscopy;
 - 23 19 ▪ no previous PIPAC-procedures.
- 24
25
26
27
28
29
30
31
32
33
34
35

36 21 Thereby, enrolment is allowed for patients with a signet ring cell carcinoma, patients with a history of
37 22 prior cytoreductive surgery or HIPEC, and patients with unresected ovarian metastases or an
38 23 unresected primary tumour (if not causing symptoms of gastrointestinal obstruction). Importantly,
39 24 enrolment is allowed for patients in various lines of palliative treatment, including patients who refuse,
40 25 have not had, or do not qualify for first-line palliative systemic therapy. All potentially eligible patients
41 26 are discussed by a multidisciplinary team. Enrolled patients are informed about the potential
42 27 consequences of postponing or discontinuing standard palliative treatment by a medical oncologist
43 28 prior to enrolment.
44
45
46
47
48
49

50 29

51 30 **Interventions and procedures**

52 31 *Figure 1* shows a flow chart of the study. *Table 1* presents a schedule of enrolment, interventions, and
53 32 assessments.
54
55
56
57
58
59
60 35

Table 1. Schedule of enrolment, interventions, and assessments.

	Enrolment/allocation	Study period			
		Outpatient clinics	Baseline radiology	Each ePIPAC-OX	1 week after each ePIPAC-OX
ENROLMENT/ALLOCATION					
Eligibility screen	X				
Informed consent	X				
INTERVENTIONS					
ePIPAC-OX			X		
Blood (organ functions, tumour markers)	X		X ^A		X
Pharmacokinetics (blood, urine, ascites, PM, normal peritoneum) ^B			X		
Translational research (blood, ascites, PM)			X ^C		
Thoracoabdominal computed tomography		X			X
Diffusion-weighted magnetic resonance imaging		X			X
Cytology (ascites or peritoneal washing)			X		
Histopathology (peritoneal biopsies)			X		
Questionnaires: quality of life		X		X	X
Questionnaires: costs ^D		X			X
ASSESSMENTS					
Baseline characteristics	X	X	X		
Toxicity			X	X	X
Environmental safety of ePIPAC-OX ^E			X		
Procedure-related characteristics			X		
Number of procedures in each patient, reasons for discontinuation			X	X	X
Postoperative complications			X	X	X
Hospital stay			X		
Readmissions				X	X
Clinical evaluation			X	X	X
Radiological tumour response		X			X
Histopathological tumour response			X		
Cytological tumour response			X		
Macroscopic tumour response			X		
Biochemical tumour response			X		X
Quality of life		X		X	X
Costs		X			X
Progression-free survival			X	X	X
Overall survival			X	X	X
ePIPAC-OX electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin; PM peritoneal metastases; ^A drawn on each postoperative day; ^B blood is drawn before ePIPAC-OX and at 5, 10, 20, 30, 60, 120, 240, 360, and 1080 minutes after oxaliplatin injection during/after the first three procedures, urine is collected before ePIPAC-OX and on postoperative days 1, 3, 5, and 7, ascites/PM/normal peritoneum are collected directly after oxaliplatin injection; ^C blood is drawn before ePIPAC-OX; ^D MCQ 4 weeks after each procedure, PCQ 4 weeks after each second procedure; ^E only during the first three procedures in the study.					

1 ePIPAC-OX

2 The procedure-related principles of (e)PIPAC have been extensively described by Willaert *et al* and
3 Giger-Pabst *et al*.^[24,48] In this study, ePIPAC-OX is performed at six-weekly intervals by at least one
4 PIPAC-qualified surgeon in a standard operating room with laminar airflow. In both study centres, the
5 operating personnel attended procedures in experienced PIPAC centres before performing their first
6 procedure. All procedures are performed under general anaesthesia. Antibiotic prophylaxis and
7 venous thromboembolism prophylaxis are not regularly administered. Before each procedure, a
8 checklist is used to ensure all materials are available. The operating personnel wears appropriate
9 chemotherapy-protective clothes according to existing HIPEC protocols.

10 The Hasson technique is used to insert a 10 mm blunt tip balloon trocar through the abdominal
11 wall. After obtaining a normothermic 12 mmHg capnoperitoneum, a second 10 mm blunt tip balloon
12 trocar is inserted under direct vision and explorative laparoscopy is performed. Only if needed, careful
13 adhesiolysis may be performed to create sufficient working space. In case of an iatrogenic bowel lesion,
14 the procedure is ended after closure of the lesion, and ePIPAC-OX may be postponed by two to four
15 weeks. If the procedure is considered feasible, leucovorin (20 mg/m² BSA in 10 minutes) and bolus 5-
16 fluorouracil (400 mg/m² BSA in 15 minutes) are administered intravenously. In the meantime, ascites
17 (or injected saline if ascites is not present) is completely evacuated, sent for cytology and translational
18 research, and the ascites volume is documented. Adhesions are scored with the Zühlke score, the
19 peritoneal cancer index (PCI) is registered, and photographs are taken throughout the peritoneal
20 cavity.^[49,50] A piece of normal peritoneum and three peritoneal metastases, preferably from
21 different areas, are biopsied, sent for histopathology and translational research, and their locations
22 are documented and marked with clips to enable biopsies of the same locations during subsequent
23 procedures.

24 Then, the ePIPAC setup is installed. A stainless steel brush electrode (Ionwand[®], Alesi Surgical,
25 Cardiff, United Kingdom) is inserted through a mini-trocar under direct vision, secured with its tip at
26 least 2 cm away from other structures, and connected to its generator (Ultravision[®], Alesi Surgical,
27 Cardiff, United Kingdom). A nebuliser (CapnoPen[®], Capnomed GmbH, Villingendorf, Germany) is
28 inserted through one of the trocars and secured with its nozzle just inside the peritoneal cavity at a
29 safe distance from visceral organs. The camera, inserted through the other trocar, is secured by a
30 laparoscope holder in a way it permanently visualises the electrode and the nebuliser. The valve of the
31 trocar connected to the CO₂ insufflation remains opened, whereas the other trocar is connected to a
32 closed aerosol waste system (CAWS) with its valve closed. The CAWS consecutively consists of a smoke
33 evacuation filter, a water seal drainage system, an infant-paediatric electrostatic microparticle filter,
34 and the air waste system of the hospital. The preoperatively prepared syringe with oxaliplatin (92
35 mg/m² BSA diluted in a total volume of 150 ml 5% dextrose) is vented, placed in a standard

1
2
3 1 angiographic injector, and connected to the nebuliser with a saline-flushed high-pressure line
4 2 protected by a plastic camera cover. A leak-free capnoperitoneum is ensured by zero-flow of CO₂. If
5 3 necessary, the external fascia may be additionally sutured and Luer lock caps may be placed on balloon
6 4 valves of trocars. The angiographic injector is installed at a flow rate of 30 ml/min and a maximum
7 5 pressure of 200 pounds per square inch. Protective films are placed on the floor below the
8 6 angiographic injector and around the patient. The angiographic injector is positioned above a
9 7 chemotherapy waste bin. The peripheral venous line of the patient is connected to a 60 ml saline-
10 8 containing syringe outside the operating room. Vital parameters of the patient, real-time
11 9 videolaparoscopy, and a patient-aimed camera are displayed on three screens outside the operating
12 10 room. The screen of the angiographic injector is positioned in front of the window of the operating
13 11 room. General anaesthesia is ensured for at least another 40 minutes. A checklist is used to confirm
14 12 that all aforementioned steps have been adequately taken. After completion of the checklist, the
15 13 entire operating personnel leaves the operating room.

16 14 Oxaliplatin is injected through the nebuliser by remote controlled activation of the
17 15 angiographic injector from outside the operating room. After complete formation of the oxaliplatin-
18 16 containing aerosol in 5 minutes, the surgeon enters the operating room and turns on the Ultravision®
19 17 generator, which results in electrostatic precipitation of the aerosol. The electrostatic field and the
20 18 capnoperitoneum are maintained for another 25 minutes. During this phase, the patient and the
21 19 procedure are monitored through the three screens and the window of the operating room. Drugs
22 20 may be administered to the patient through the intravenous access outside the operating room if
23 21 necessary.

24 22 After 25 minutes, the surgeon enters the operating room, turns off the Ultravision®
25 23 generator, closes the trocar valve connected to the CO₂ insufflation, and opens the trocar valve
26 24 connected to the CAWS. After complete evacuation of the aerosol, the electrode and the nebuliser are
27 25 removed, the entire operating personnel enters the operating room, and a new capnoperitoneum is
28 26 obtained. Ascites and peritoneal biopsies are collected for pharmacokinetic purposes. In case no
29 27 bleeding or perforations are observed, instruments are removed and incisions are closed with
30 28 absorbable sutures. All instruments and materials are directly disposed in chemotherapy waste bins
31 29 and the operating room is cleaned according to existing HIPEC protocols. Any procedure-related
32 30 mistake or difficulty during ePIPAC-OX is recorded directly after occurrence.

33 31 After ePIPAC-OX, patients are admitted to the general surgical ward. To relieve postoperative
34 32 pain, patients receive paracetamol (1 g, four times daily), on-demand morphine, and 1 g of metamizole
35 33 directly after the procedure. To minimise postoperative nausea and vomiting, patients receive
36 34 perioperative dexamethasone and on-demand granisetron (1 mg, three times daily). Standard post-
37 35 surgical clinical evaluations are performed a few hours after the procedure and on every postoperative

1 day. Blood is drawn for bone marrow, liver, and kidney functions, albumin, and C-reactive protein on every postoperative day. If the postoperative period is uneventful, patients are discharged on the first postoperative day. All body excretes are considered oxaliplatin-contaminated for up to five days after the procedure.

Dose reduction, prohibited and permitted concomitant care, and strategies to improve adherence are not specified *a priori*, but left to the discretion of the treating physician. ePIPAC-OX is repeated until clinical progression, radiological progression (Response Evaluation Criteria In Solid Tumours or at physician's discretion in case of non-measurable disease), macroscopic progression (i.e. ascites volume, PCI), unacceptable toxicity, physician's decision to discontinue, or at patient's request to discontinue. In patients who develop systemic metastases, continuation of ePIPAC-OX can only be considered if the patient has no systemic palliative treatment options and stable peritoneal disease.

Outpatient evaluations

One week after each ePIPAC-OX, patients undergo clinical evaluation by phone. Four weeks after each ePIPAC-OX, patients undergo radiological evaluation (i.e. thoracoabdominal CT, diffusion-weighted magnetic resonance imaging [DW-MRI]), biochemical evaluation (i.e. bone marrow, liver, and kidney functions, albumin, C-reactive protein, tumour markers), and clinical evaluation.

Questionnaires

Patients are asked to complete EQ-5D-5L, QLQ-C30, and QLQ-CR29 at baseline and one and four weeks after each ePIPAC-OX.[51-53] iMTA Productivity Cost Questionnaire (PCQ) and iMTA Medical Consumption Questionnaire (MCQ) are sent to the patients at baseline and four weeks after each ePIPAC-OX (PCQ) and each second ePIPAC-OX (MCQ).[54,55]

Pharmacokinetics

Blood is collected during and after the first three procedures in each patient. Four ml of whole blood is drawn and collected in heparin tubes before ePIPAC-OX and at 5, 10, 20, 30, 60, 120, 240, 360, and 1080 minutes after injection of oxaliplatin. After immediate centrifuging, an aliquot of plasma is stored at -80°C until analysis. Another aliquot of 1 ml of plasma is centrifuged through an ultrafiltration membrane and stored at -80°C until analysis. Urine, ascites, peritoneal metastases, and normal peritoneum are collected during and after all procedures. Four ml of urine is collected in urinalysis tubes before ePIPAC-OX and on the first postoperative day. These are stored at -20°C until analysis. After discharge, patients are asked to collect four ml of urine in urinalysis tubes on the third, fifth, and seventh postoperative day, and to store these specimens at their home address at -20°C until analysis. After electrostatic precipitation of the aerosol, the surgeon aspirates a few ml of ascites and biopsies

1 two peritoneal metastases and two pieces of normal peritoneum, preferably from different locations.
2 These are collected in aliquots and directly stored at -80°C until analysis. Concentrations of oxaliplatin
3 are measured by using atomic absorption spectrophotometry.
4

5 Translational research

6 Before each ePIPAC-OX, 20 ml of blood is drawn and collected in 10 ml Cell-free DNA BCT tubes (Streck,
7 La Vista, NE, USA). According to the manufacturer's instructions, these tubes are sent to a central lab
8 for isolation and storage (-80°C) of plasma and cell pellet. Collected ascites or saline is centrifuged
9 twice (5 minutes, 420 g, zero break) under sterile conditions. The supernatant is snap frozen and stored
10 at -80°C for further analysis on soluble components. The cell pellet is suspended in organoid culture
11 medium at 4°C for transport and further work up. Of each collected PM, three parts are snap frozen
12 and stored at -80°C for sequencing analysis.
13

14 Outcomes

15 An assessment schedule is presented in *Table 1*. The primary outcome is the number of patients with
16 major toxicity, defined as grade ≥ 3 according to the Common Terminology Criteria for Adverse Events
17 (CTCAE) v4.0,[56] up to four weeks after the last ePIPAC-OX. Secondary outcomes are:

- 18
- 19 ▪ the environmental safety of ePIPAC-OX, based on air and surface concentrations of oxaliplatin
20 during the first three procedures, measured by atomic absorption spectrophotometry;
- 21 ▪ procedure-related characteristics of ePIPAC-OX (e.g. intraoperative complications, amount of
22 adhesions, procedure-related mistakes and difficulties, operating time);
- 23 ▪ the number of procedures in each patient and reasons for discontinuation;
- 24 ▪ minor toxicity, defined as grade ≤ 2 according to CTCAE v4.0,[56] up to four weeks after the last
25 ePIPAC-OX;
- 26 ▪ major and minor postoperative complications, defined as grade ≥ 3 and grade ≤ 2 according to
27 Clavien-Dindo,[57] respectively, up to four weeks after the last ePIPAC-OX;
- 28 ▪ hospital stay, defined as the number of days between ePIPAC-OX and initial discharge;
- 29 ▪ readmissions, defined as any hospital admission after initial discharge, up to four weeks after
30 the last ePIPAC-OX;
- 31 ▪ radiological tumour response, based on central review of thoracoabdominal CT and DW-MRI
32 at baseline and four weeks after each ePIPAC-OX, performed by two independent radiologists
33 (JN, MLH) blinded to clinical outcomes (classification is not defined *a priori*);

- 1
- 2
- 3 1 ▪ histopathological tumour response, based on central review of collected peritoneal biopsies
- 4 2 during each ePIPAC-OX, performed by two independent pathologists (e.g. CJRH) blinded to
- 5 3 clinical outcomes by using the Peritoneal Regression Grading Score;[58]
- 6 4 ▪ macroscopic tumour response, based on PCI and ascites volume during each ePIPAC-OX;
- 7 5 ▪ biochemical tumour response, based on tumour markers measured at different time points
- 8 6 (Table 1);
- 9 7 ▪ cytological tumour response, based on collected ascites or peritoneal washing cytology during
- 10 8 each ePIPAC-OX;
- 11 9 ▪ quality of life, extracted from questionnaires (EQ-5D-5L, QLQ-C30, QLQ-CR29) at different time
- 12 10 points (Table 1);
- 13 11 ▪ costs, derived from the Dutch costing guidelines for health care research at the time of
- 14 12 analysis, based on case report forms, hospital information systems, and questionnaires (iMTA
- 15 13 PCQ, iMTA MCQ) at different time points (Table 1);
- 16 14 ▪ progression-free survival, defined as the time between enrolment and clinical, radiological, or
- 17 15 macroscopic progression, or death;
- 18 16 ▪ overall survival, defined as the time between enrolment and death;
- 19 17 ▪ the pharmacokinetics of oxaliplatin during and after ePIPAC-OX.
- 20 18
- 21 19
- 22 20
- 23 21
- 24 22
- 25 23
- 26 24
- 27 25
- 28 26
- 29 27
- 30 28
- 31 29
- 32 30
- 33 31
- 34 32
- 35 33
- 36 34
- 37 35
- 38 36
- 39 37
- 40 38
- 41 39
- 42 40
- 43 41
- 44 42
- 45 43
- 46 44
- 47 45
- 48 46
- 49 47
- 50 48
- 51 49
- 52 50
- 53 51
- 54 52
- 55 53
- 56 54
- 57 55
- 58 56
- 59 57
- 60 58

19 **Sample size**

20 Given the absence of evident clinical endpoint in this patient category, the investigators pragmatically
 21 determined the sample size of this exploratory study. The investigators agreed that 60 procedures are
 22 required to explore the feasibility, safety, tolerability, and preliminary efficacy of repetitive ePIPAC-OX
 23 in this setting. Since the expected mean number of procedures is three per patient,[36] the initial
 24 sample size is determined at 20 patients. This pragmatically determined sample size is approved by
 25 the central ethics committee. Enrolled patients who do not undergo a first ePIPAC-OX (e.g. systemic
 26 metastases on baseline radiology, non-access, resectable disease) are replaced to enrol 20 patients
 27 who receive at least one ePIPAC-OX.

29 **Recruitment**

30 The study started in October 2017 and is currently enrolling patients. The investigators anticipate that
 31 20 patients will be enrolled within a maximum of three years. Strategies for achieving adequate
 32 participant enrolment are not defined *a priori*.

34 **Data collection and data management**

1 Outcomes are collected in all patients who receive at least one ePIPAC-OX. All baseline characteristics
2 and clinical outcomes are prospectively collected and entered in an ISO 27001 certified central study
3 database (De Research Manager, Deventer, Netherlands) with study-specific electronic case report
4 forms by a local investigator in each study centre (RJL, ECEW). This ISO 27001 certified system ensures
5 adequate data integrity, including data coding, security, and storage. Questionnaires (quality of life,
6 costs), peritoneal biopsies (histopathological response), and radiological examinations (radiological
7 response) are collected by the coordinating investigator (KPR) throughout the study and centrally
8 analysed after study completion. Plans to promote data quality, participant retention, and complete
9 follow-up are not specified *a priori*.

11 **Statistical methods**

12 Repetitive continuous outcomes (e.g. quality of life, operating time) are analysed by using the
13 Wilcoxon signed-rank test, the paired samples t-test, the Friedman test, or repeated measurements
14 analysis of variance where appropriate. Repetitive categorical outcomes (e.g. intraoperative
15 complications, postoperative complications) are analysed by using the McNemar test, the Wilcoxon
16 signed-rank test, the Cochran's Q test, or generalised estimating equations where appropriate. Time-
17 to-event variables (i.e. overall and progression-free survival) are analysed and displayed by using the
18 Kaplan-Meier method. Other outcomes are analysed by using descriptive statistics. All statistical tests
19 are two-sided and $p < 0.05$ is considered statistically significant.

21 **Data monitoring**

22 Interim analyses are performed after 8 and 20 procedures. The study is terminated after these interim
23 analyses if CTCAE grade ≥ 3 toxicity, directly related to ePIPAC-OX, is observed after ≥ 4 and ≥ 10
24 procedures. Furthermore, the study is directly terminated if more than one CTCAE grade 5 toxicity,
25 directly related to ePIPAC-OX, occurs during the study. The coordinating investigator and the principal
26 investigator (IHJTH) have access to these interim results. The principal investigator makes the decision
27 to terminate or continue the study. The investigators decided that a data monitoring committee is not
28 needed given the clear stopping rules and the low expected toxicity of repetitive ePIPAC-OX.

30 **Harms**

31 Local investigators report all serious adverse events (SAEs) or suspected unexpected serious adverse
32 reactions (SUSARs) to the coordinating investigator within 24 hours. The coordinating investigator
33 reports SAEs/SUSARs to the ethics committee within seven days of first knowledge for lethal or life
34 threatening SAEs/SUSARs, and within fifteen days for other SAEs/SUSARs. The time window for
35 reporting SAEs/SUSARs is from enrolment up to four weeks after the last ePIPAC-OX.

1
2
3 1
4
5 2 **Auditing**
6
7 3 The study is audited by independent qualified monitors of Clinical Trial Centre Maastricht (Maastricht,
8
9 4 Netherlands) as a high-risk study according to the brochure 'Kwaliteitsborging mensgebonden
10
11 5 onderzoek 2.0' by the Dutch Federation of University Medical Centres. This means that study centres
12
13 6 are audited at least three times per year, depending on enrolment, with 100% auditing of the study
14
15 7 master file, investigator site files, informed consent forms, eligibility criteria, source data verification,
16
17 8 and SAEs/SUSARs.
18
19 9

10 **Patient and public involvement**

11 Patients were not involved in the study design before the start of the study. Shortly after the start of
12
13 12 the study, the investigators presented the study design to a patient advisory group. Major topics of
14
15 13 discussion were the rationale for the study, outcome parameters, recruitment strategies, the patient
16
17 14 information sheet, dissemination strategies, and the potential risks, benefits, and burden of
18
19 15 participation from the patient's perspective. The patient advisory group supported the presented
20
21 16 study design. Although the patient advisory group is not involved in the recruitment and the conduct
22
23 17 of the study, they will be involved in plans to disseminate the study results to relevant patient groups.
24
25 18

19 **ETHICS AND DISSEMINATION**

20 **Research ethics approval**

21 This study is approved by an ethics committee (MEC-U, Nieuwegein, Netherlands, R17.038), the Dutch
22
23 22 competent authority (Centrale Commissie Mensgebonden Onderzoek, NL60405.100.17), and the
24
25 23 institutional review boards of Catharina Hospital (Lokale Uitvoerbaarheidscommissie, CZE-2017.50)
26
27 24 and St. Antonius Hospital (R&D, L18.021).
28
29 25

26 **Protocol amendments**

27 Important protocol modifications are communicated to the ethics committee, the Dutch competent
28
29 28 authority, the institutional review boards of both study centres, all investigators, and trial registries.
30
31 29

30 **Consent or assent**

31 Written informed consent is obtained by local investigators at the outpatient clinic of the study
32
33 32 centres. Patients are given the possibility to give separate permission for undergoing DW-MRI and for
34
35 33 storage of specimens for translational research.
36
37 34

35 **Confidentiality**

1
2
3 1 Personal information about potential and enrolled patients is collected, shared, and maintained
4
5 2 according to the Dutch law (Wet Bescherming Persoonsgegevens).
6
7 3

8 4 **Declaration of interests**

9
10 5 The investigators declare no competing interests. The funders have no role in the study design, in
11
12 6 writing the report, or in the decision to submit the report for publication.
13
14 7

15 8 **Access to data**

16
17 9 All investigators have access to the final datasets, without contractual agreements that limit such
18
19 10 access.
20
21 11

22 12 **Ancillary and post-study care**

23
24 13 The sponsor (Catharina Hospital, Eindhoven, Netherlands) is insured to provide cover for patients who
25
26 14 suffer harm from study participation. After discontinuation of ePIPAC-OX, patients receive standard
27
28 15 palliative treatment for unresectable metastatic colorectal cancer according to Dutch guidelines.[4]
29
30 16

31 17 **Dissemination policy**

32
33 18 Results of the study are personally communicated to participants and intended for publication in peer-
34
35 19 reviewed medical journals and for presentation to patients, healthcare professionals, and other
36
37 20 stakeholders. Authorship eligibility guidelines for the main manuscript and manuscript of side studies
38
39 21 are not defined *a priori*. The full protocol and Dutch informed consent forms are, or will become,
40
41 22 available upon reasonable request.
42
43 23

44 24 **DISCUSSION**

45
46 25 To the knowledge of the investigators, this is the first study that prospectively explores the feasibility,
47
48 26 safety, tolerability, costs, preliminary efficacy, and pharmacokinetics of repetitive ePIPAC-OX as a
49
50 27 palliative monotherapy in patients with isolated unresectable colorectal PM.

51
52 28 This study protocol has potential limitations. The broad eligibility criteria could lead to a
53
54 29 heterogeneous cohort with various primary tumours (i.e. colon, appendix) and histologies (e.g. signet
55
56 30 ring cell carcinoma, high-grade appendiceal mucinous neoplasm) in different lines of treatment. This
57
58 31 clinical heterogeneity could impede the interpretation of survival outcomes. However, survival
59
60 32 outcomes are not the major focus of this study. Enrolment is also allowed for patients with an
33
34 33 unresected primary tumour and patients who did not receive prior palliative systemic therapy. In these
35
36 34 patients, administration of repetitive ePIPAC-OX as a monotherapy could theoretically lead to
37
38 35 undertreatment and subsequent systemic progression or progression of the primary tumour.

1
2
3 1 However, it is thought that the frequent clinical and radiological evaluations detect such progression
4 2 in a sufficiently early stage. Moreover, patients need to be informed by a medical oncologist about the
5 3 potential consequences of postponing or discontinuing their standard palliative treatment prior to
6 4 enrolment. Conclusively, the investigators feel that these controlled circumstances justify enrolment
7 5 of these patients.
8
9

10 6 This study protocol has potential strengths. All endpoints are predefined and prospectively
11 7 assessed. Independent 100% auditing ensures an appropriately conducted study and high-quality data.
12 8 Unlike other studies, repetitive ePIPAC-OX is administered as a palliative monotherapy in all patients.
13 9 Thereby, outcomes are not influenced by concurrent palliative systemic therapy. Extensive assessment
14 10 of quality of life provides insights in the tolerability of ePIPAC-OX from a patient perspective, whereas
15 11 pharmacokinetic analyses provide the first insights in the systemic absorption repetitive ePIPAC-OX.
16 12 Insights in the costs of ePIPAC-OX could be valuable for policy makers and other teams that aim to
17 13 implement this procedure or apply for scientific grants, while translational side studies may open new
18 14 avenues for research.
19
20
21
22
23
24
25
26
27

28 16 REFERENCES

- 29
30 17 [1] van Gestel YR, de Hingh IH, van Herk-Sukel MP, et al. Patterns of metachronous metastases after
31 18 curative treatment of colorectal cancer. *Cancer Epidemiol* 2014;38:448-54.
32
33 19 [2] van der Geest LG, Lam-Boer J, Koopman M, et al. Nationwide trends in incidence, treatment and
34 20 survival of colorectal cancer patients with synchronous metastases. *Clin Exp Metastasis* 2015;32:457-
35 21 65.
36
37 22 [3] Razenberg LG, Lemmens VE, Verwaal VJ, et al. Challenging the dogma of colorectal peritoneal
38 23 metastases as an untreatable condition: results of a population-based study. *Eur J Cancer* 2016;65:113-
39 24 20.
40
41 25 [4] Landelijke werkgroep Gastro Intestinale Tumoren. Richtlijn colorectaal carcinoom. 2014.
42 26 <https://www.oncoline.nl/colorectaalcarcinoom>. Accessed 10 Dec 2018.
43
44 27 [5] Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer
45 28 given systemic therapy: an analysis of individual patient data from prospective randomised trials from
46 29 the Analysis and Research in Cancers of the Digestive System (ARCAD) database. *Lancet Oncol*
47 30 2016;17:1709-19.
48
49 31 [6] Sugarbaker PH, Stuart OA, Vidal-Jove J, et al. Pharmacokinetics of the peritoneal-plasma barrier
50 32 after systemic mitomycin C administration. *Cancer Treat Res* 1996;82:41-52.
51
52 33 [7] Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug
53 34 administration in the treatment of ovarian cancer. *Cancer Treat Rep* 1978;62:1-11.
54
55 35 [8] Jacquet P, Sugarbaker PH. Peritoneal-plasma-barrier. *Cancer Treat Res* 1996;82:53-63.
56
57
58
59
60

- 1
2
3 1 [9] Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue
4 2 penetration and surface exposure. *J Natl Cancer Inst* 1997;89:480-7.
- 5 3 [10] Markman M. Limited use of the intraperitoneal route for ovarian cancer – why? *Nat Rev Clin Oncol*
6 4 2015;12:628-30.
- 7 5 [11] Solass W, Hetzel A, Schwarz T, et al. PIPAC Technology. In: Reymond MA, Solass W. Pressurized
8 6 IntraPeritoneal Aerosol Chemotherapy – Cancer under Pressure. De Gruyter, 2014.
- 9 7 [12] Reymond MA, Hu B, Garcia A, et al. Feasibility of therapeutic pneumoperitoneum in a large animal
10 8 model using a microvaporisator. *Surg Endosc* 2000;14:51-5.
- 11 9 [13] Jacquet P, Stuart OA, Chang D, et al. Effects of intra-abdominal pressure on pharmacokinetics and
12 10 tissue distribution of doxorubicin after intraperitoneal administration. *Anticancer Drugs* 1996;7:596-
13 11 603.
- 14 12 [14] Esquis P, Consolo D, Magnin G, et al. High intra-abdominal pressure enhances the penetration and
15 13 antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. *Ann Surg*
16 14 2006;244:106-12.
- 17 15 [15] Solass W, Herbette A, Schwarz T, et al. Therapeutic approach of human peritoneal carcinomatosis
18 16 with Dbait in combination with capnoperitoneum: proof of concept. *Surg Endosc* 2012;26:847-52.
- 19 17 [16] Solass W, Hetzel A, Nadiradze G, et al. Description of a novel approach for intraperitoneal drug
20 18 delivery and the related device. *Surg Endosc* 2012;26:1849-55.
- 21 19 [17] Facy O, Al Samman S, Magnin G, et al. High pressure enhances the effect of hyperthermia in
22 20 intraperitoneal chemotherapy with oxaliplatin: an experimental study. *Ann Surg* 2012;256:1084-8.
- 23 21 [18] Solass W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis
24 22 using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. *Ann Surg Oncol*
25 23 2014;21:553-9.
- 26 24 [19] Blanco A, Giger-Pabst U, Solass W, et al. Renal and hepatic toxicities after pressurized
27 25 intraperitoneal aerosol chemotherapy (PIPAC). *Ann Surg Oncol* 2013;20:2311-6.
- 28 26 [20] Eveno C, Haidara A, Ali I, et al. Experimental pharmacokinetics evaluation of chemotherapy
29 27 delivery by PIPAC for colon cancer: first evidence for efficacy. *Pleura and Peritoneum* 2017;2:103-109.
- 30 28 [21] Grass F, Vuagnieaux A, Teixeira-Farinha H, et al. Systematic review of pressurized intraperitoneal
31 29 aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. *Br J Surg*
32 30 2017;104:669-78.
- 33 31 [22] Tempfer C, Giger-Pabst U, Hilal Z, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
34 32 for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special
35 33 emphasis on ovarian cancer. *Arch Gynecol Obstet* 2018;298:243-57.
- 36 34 [23] Nowacki M, Alyami M, Villeneuve L, et al. Multicenter comprehensive methodological and
37 35 technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions

- 1 performed in 349 patients for peritoneal carcinomatosis treatment: an international survey study. *Eur*
2 *J Surg Oncol* 2018;44:991-6.
- 3 [24] Willaert W, Sessink P, Ceelen W. Occupational safety of pressurized intraperitoneal aerosol
4 chemotherapy (PIPAC). *Pleura and Peritoneum* 2017;2:121-8.
- 5 [25] Graversen M, Lundell L, Fristrup C, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
6 as an outpatient procedure. *Pleura and Peritoneum* 2018;20180128.
- 7 [26] Kakchekeeva T, Demtröder C, Herath NI, et al. In vivo feasibility of electrostatic precipitation as an
8 adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC). *Ann Surg Oncol* 2016;23(Suppl
9 5):592-8.
- 10 [27] Odendahl K, Solass W, Demtröder C, et al. Quality of life of patients with end-stage peritoneal
11 metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). *Eur J Surg Oncol*
12 2015;41:1379-85.
- 13 [28] Robella M, Vaira M, de Simone M. Safety and feasibility of pressurized intraperitoneal aerosol
14 chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat
15 peritoneal carcinomatosis. *World J Surg Oncol* 2016;14:128.
- 16 [29] Teixeira Farinha H, Grass F, Kefleyesus A, et al. Impact of pressurized intraperitoneal aerosol
17 chemotherapy on quality of life and symptoms in patients with peritoneal carcinomatosis: a
18 retrospective cohort study. *Gastroenterol Res Pract* 2017;2017:4596176.
- 19 [30] Hübner M, Teixeira Farinha H, Grass F, et al. Feasibility and safety of pressurized intraperitoneal
20 aerosol chemotherapy for peritoneal carcinomatosis: a retrospective cohort study. *Gastroenterol Res*
21 *Pract* 2017;2017:6852749.
- 22 [31] Hübner M, Grass F, Teixeira-Farinha H, et al. Pressurized intraperitoneal aerosol chemotherapy –
23 practical aspects. *Eur J Surg Oncol* 2017;43:1102-9.
- 24 [32] Alyami M, Gagniere J, Sgarbura O, et al. Multicentric initial experience with the use of the
25 pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable
26 peritoneal carcinomatosis. *Eur J Surg Oncol* 2017;43:2178-83.
- 27 [33] Graversen M, Detlefsen S, Bjerregaard JK, et al. Prospective, single-center implementation and
28 response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal
29 metastasis. *Ther Adv Med Oncol* 2018;10:1758835918777036.
- 30 [34] Kurtz F, Struller F, Horvath P, et al. Feasibility, safety, and efficacy of pressurized intraperitoneal
31 aerosol chemotherapy (PIPAC) for peritoneal metastasis: a registry study. *Gastroenterol Res Pract*
32 2018;2018:2743985.
- 33 [35] Teixeira Farinha H, Grass F, Labгаа I, et al. Inflammatory response and toxicity after pressurized
34 intraperitoneal aerosol chemotherapy. *J Cancer* 2018;9:13-20.

- 1
2
3 1 [36] Demtröder C, Solass W, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy with
4 2 oxaliplatin in colorectal peritoneal metastasis. *Colorectal Dis* 2016;18:364-71.
- 5 3 [37] Graversen M, Detlefsen S, Pfeiffer P, et al. Severe peritoneal sclerosis after repeated pressurized
6 4 intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature
7 5 survey. *Clin Exp Metastasis* 2018;35:103-8.
- 8 6 [38] Siebert M, Alyami M, Mercier F, et al. Severe hypersensitivity reactions to platinum compounds
9 7 post-pressurized intraperitoneal aerosol chemotherapy (PIPAC): first literature report. *Cancer
10 8 Chemother Pharmacol* Published Online First: 3 Dec 2018. doi: 10.1007/s00280-018-3740-3.
- 11 9 [39] Clinicaltrials.gov. www.clinicaltrials.gov. Accessed 10 Dec 2018.
- 12 10 [40] Solass W, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC):
13 11 occupational health and safety aspects. *Ann Surg Oncol* 2013;20:3504-11.
- 14 12 [41] Graversen M, Pedersen PB, Mortensen MB. Environmental safety during the administration of
15 13 Pressurized intraperitoneal aerosol chemotherapy (PIPAC). *Pleura and Peritoneum* 2016;1:203-8.
- 16 14 [42] Ndaw S, Hanser O, Kenepekian V, et al. Occupational exposure to platinum drugs during
17 15 intraperitoneal chemotherapy. Biomonitoring and surface contamination. *Toxicol Lett* 2018;298:171-
18 16 6.
- 19 17 [43] Ametsbichler P, Böhlant A, Nowak D, et al. Occupational exposure to cisplatin/oxaliplatin during
20 18 pressurized intraperitoneal aerosol chemotherapy (PIPAC)? *Eur J Surg Oncol* 2018;44:1793-9.
- 21 19 [44] Dumont F, Senellart H, Pein F, et al. Phase I/II study of oxaliplatin dose escalation via a laparoscopic
22 20 approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable
23 21 peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): rationale and design.
24 22 *Pleura and Peritoneum* 2018;20180120
- 25 23 [45] Kim G, Tan HL, Chen E, et al. Study protocol: phase 1 dose escalating study of pressurized
26 24 intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis. *Pleura and
27 25 Peritoneum* 2018;20180118.
- 28 26 [46] Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after
29 27 complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. *Ann Oncol*
30 28 2002;13:267-72.
- 31 29 [47] Giachetti S, Perpoint B, Zidani R, et al. Phase III multicentre randomized trial of oxaliplatin added
32 30 to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. *J
33 31 Clin Oncol* 2000;18:136-47.
- 34 32 [48] Giger-Pabst U, Tempfer CB. How to perform safe and technically optimized pressurized
35 33 intraperitoneal aerosol chemotherapy (PIPAC): experience after a consecutive series of 1200
36 34 procedures. *J Gastrointest Surg* 2018;22:2187-93.

- 1
2
3 1 [49] Zühlke HV, Lorenz EM, Straub EM, et al. Pathophysiology and classification of adhesions.
4 2 *Langenbecks Arch Chir II Verh Dtsch Ges Chir* 1990;1009-16.
5 3 [50] Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients
6 4 with peritoneal carcinomatosis. *Cancer Treat Res* 1996;82:359-74.
7 5 [51] Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level
8 6 version of EQ-5D (EQ-5D-5L). *Qual Life Res* 2011;20:1727-36.
9 7 [52] Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and
10 8 Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in
11 9 oncology. *J Natl Cancer Inst* 1993;85:365-76.
12 10 [53] Stiggelbout AM, Kunneman M, Baas-Thijssen MC, et al. The EORTC QLQ-CR29 quality of life
13 11 questionnaire for colorectal cancer: validation of the Dutch version. *Qual Life Res* 2016;25:1853-8.
14 12 [54] Bouwmans C, Krol M, Severens H, et al. The iMTA Productivity Cost Questionnaire: a standardized
15 13 instrument for measuring and valuing health-related productivity losses. *Value Health* 2015;18:753-8.
16 14 [55] iMTA: questionnaires. <https://www.imta.nl/questionnaires/>. Accessed 10 Dec 2018.
17 15 [56] Common Terminology Criteria for Adverse Events (CTCAE) v4.0. National Cancer Institute. 2009.
18 16 [https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-](https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf)
19 17 [29_QuickReference_8.5x11.pdf](https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf). Accessed 10 Dec 2018.
20 18 [57] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with
21 19 evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;240:205-13.
22 20 [58] Solass W, Sempoux C, Carr N, et al. Reproducibility of the Peritoneal Regression Grading Score
23 21 (PRGS) for assessment of response to therapy in peritoneal metastasis. *Histopathology* Published
24 22 Online First: 27 Jan 2019. doi:10.1111/his.13829.

23 24 **ACKNOWLEDGEMENTS**

25 26 None.

27 28 **AUTHORS' CONTRIBUTIONS**

29 30 KPR is the coordinating investigator. RJL, AMJT, GMC, JWAB, and SWN are the local investigators of the
31 32 first study centre. ECEW, TJMK, ML, MJW, and DB are the local investigators of the second study centre.
33 34 RT performs the pharmacokinetic analyses. MJD is the study pharmacologist supervising the
35 36 pharmacokinetic analyses. JN and MJL are the study radiologists performing the central radiological
37 38 review. CJRH is the study pathologist performing the central histopathological review. HJS is the study
39 40 anaesthesiologist who developed the protocols for perioperative care. IE and RJAF are responsible for
41 42 translational research on blood. AC and OK are responsible for translational research on ascites and
43 44 PM. IHJTH is the principal investigator. KPR, RJL, and IHJTH made substantial contributions to

1
2
3 1 conception and design of the study, drafted the protocol, and drafted the manuscript. ECEW, TJMK,
4 HJS, RT, MJD, JN, MJL, CJRH, IE, RJAF, AC, OK, ML, AMJT, GMC, JWAB, MJW, DB, and SWN made
5 2 substantial contributions to conception and design of the study and critically revised the protocol and
6 3 the manuscript for important intellectual content. KPR, RJL, ECEW, TJMK, HJS, RT, MJD, JN, MJL, CJRH,
7 4 IE, RJAF, AC, OK, ML, AMJT, GMC, JWAB, MJW, DB, SWN, and IHJTH gave final approval of the version
8 5 to be published and agree to be accountable for all aspects of the work.
9 6
10 7

8 **DATA SHARING**

15 8
16 9 All data relevant to the study will be included in the article or uploaded as supplementary information.
17 10 This will not include patient identifiable data.
18 11

12 **FUNDING**

20 12
21 13 This study is supported by Catharina Research Foundation (grant number: 2017-5) and St. Antonius
22 14 Research Foundation (grant number: 17.4).
23 15

26 16 **COMPETING INTERESTS**

27 17 None declared.
28 18

30 19 **ETHICAL APPROVAL**

31 20 This study is approved by an ethics committee (MEC-U, Nieuwegein, Netherlands, number R17.038),
32 21 the Dutch competent authority (CCMO, The Hague, Netherlands), and the institutional review boards
33 22 of both study centres.
34 23

35 24 **DATA SHARING**

36 25 Not applicable.
37 26

38 27 **PATIENT CONSENT**

39 28 Not applicable.
40 29

41 30 **PROTOCOL VERSION**

42 31 Version 6, 10 January 2019
43 32

44 33 **FIGURE TITLES**

45 34 **Figure 1.** Flow chart of the CRC-PIPAC study
46 35

1
2
3 **1 FIGURE LEGENDS**

4
5 2 Figure 1. *ePIPAC-OX* electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin;

6
7 3 **B** Bloods (organ functions, tumour markers)

8
9 4 **c** Cytology (ascites or peritoneal washing with saline)

10
11 5 **H** Histopathology (peritoneal biopsies)

12
13 6 **P** Pharmacokinetics (blood, urine, ascites, PM, normal peritoneum)


14
15 7 **Q** Questionnaires (quality of life, costs)

16
17 8 **R** Radiology (thoracoabdominal CT, diffusion-weighted MRI)

18
19 9 **T** Translational research (blood, ascites, PM)

20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
	2b	All items from the World Health Organization Trial Registration Data Set	Entire manuscript
Protocol version	3	Date and version identifier	20
Funding	4	Sources and types of financial, material, and other support	20
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1-2, 19-20
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	14
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	Entire manuscript

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention **3-5**

4

5

6 6b Explanation for choice of comparators **Not applicable**

7

8 Objectives 7 Specific objectives or hypotheses **5**

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) **6**

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained **6**

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) **6**

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered **6-11**

23

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) **9**

26

27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) **9**

29

30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial **9**

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended **11-12**

35

36

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) **Table 1, Figure 1**

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	12
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	12
5				

Methods: Assignment of interventions (for controlled trials)

Allocation:

10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Not applicable
11				
12				
13				
14				
15				
16	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	Not applicable
17				
18				
19				
20				
21	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	Not applicable
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	Not applicable
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	Not applicable
28				
29				
30				

Methods: Data collection, management, and analysis

33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	12
34				
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	12
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	12
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	13
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	Not applicable
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	12
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	13
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	13
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	13
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	13
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	14
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	14
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	14
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	14
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	14
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	14
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	14
14				
15				
16				
17	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	15
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	15
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	15
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	15
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Available upon request
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	10
35				
36				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons [“Attribution-NonCommercial-NoDerivs 3.0 Unported”](https://creativecommons.org/licenses/by/4.0/) license.